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ABSTRACT OF THE DISSERTATION 
 
Functional Characterization of Oncogenic Driver FGFR3-TACC3 
 
by 
 
Katelyn N. Nelson 
Doctor of Philosophy in Chemistry 
University of California San Diego, 2018 
Professor Daniel J. Donoghue, Chair 
 
 Fibroblast Growth Factor Receptors (FGFRs) are critical for cell proliferation and 
differentiation. Mutation and/or translocation of FGFRs lead to aberrant signaling that often 
results in developmental syndromes or cancer growth. As sequencing of human tumors 
becomes more frequent, so does the emergence of FGFR translocations and fusion proteins. 
The research conducted in this work will focus on a frequently identified fusion protein 
between FGFR3 and transforming acidic coiled-coil containing protein 3 (TACC3). As 
detailed in this dissertation, it is apparent that the fused coiled-coil TACC3 domain results in 
 xv 
constitutive phosphorylation of key activating FGFR3 tyrosine residues. The presence of the 
TACC coiled-coil domain leads to increased and altered levels of FGFR3 activation, fusion 
protein phosphorylation, MAPK pathway activation, nuclear localization, cellular 
transformation, and IL3-independent proliferation. Introduction of K508R FGFR3 kinase 
dead mutation abrogates these effects, except for nuclear localization which is due solely to 
the TACC3 domain. We further demonstrate that the oncogenic effects initiated by FGFR3-
TACC3 are dependent on the overactivation of the MAPK pathway and localization of 
FGFR3-TACC3 to the secretory pathway or the plasma membrane. The activation of the 
MAPK pathway is essential for cell transformation but involvement in the cell cycle via the 
canonical TACC3 pathways is not. Additionally, we have shown that kinase inhibitors for 
MEK (Trametinib) and FGFR (BGJ398) are effective in blocking cell transformation and 
MAPK pathway upregulation. The need for precision medicine is evidenced by the different 
effects these inhibitors have against various FGFR3-TACC3 breakpoints. The existence of 
FGFR3-TACC3 fusions in human cancers creates additional challenges and opportunities for 
identifying effective treatment strategies. The development of such personalized medicines 
will be essential in treating patients who harbor oncogenic drivers such as FGFR3-TACC3.  
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CHAPTER 1 
 
Functions of Fibroblast Growth Factor Receptors in Cancer Defined by Novel 
Translocations 
 
 
 
 
 
ABSTRACT 
The four receptor tyrosine kinases (RTKs) within the family of Fibroblast Growth 
Factor Receptors (FGFRs) are critical for normal development but also play an enormous role 
in oncogenesis. Mutations and/or abnormal expression often lead to constitutive dimerization 
and kinase activation of FGFRs, and represent the primary mechanism for aberrant signaling. 
Sequencing of human tumors has revealed a plethora of somatic mutations in FGFRs that are 
frequently identical to germline mutations in developmental syndromes, and has also 
identified novel FGFR fusion proteins arising from chromosomal rearrangements that 
contribute to malignancy. This chapter reviews approximately 40 different fusion proteins 
created by translocations involving FGFRs that have been identified in human cancer. This 
chapter discusses the effects of these genetic alterations on downstream signaling cascades, 
and the challenge of drug resistance in cancer treatment with antagonists of FGFRs.  
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1.1 OVERVIEW OF CANONICAL FGFR SIGNALING 
 Receptor tyrosine kinases (RTKs) represent important signal transducers in the cell 
membrane and are comprised of nearly twenty families of homologous proteins in humans, 
with almost 60 distinct members (1). In the FGFR family, four homologous human receptors 
have been identified: FGFR1, FGFR2, FGFR3 and FGFR4. All of the FGFRs exhibit three 
extracellular immunoglobulin (Ig)-like domains, a membrane-spanning segment and a split 
tyrosine kinase domain. Fibroblast growth factors (FGFs), a large family of related growth 
factors, act in concert with heparin sulfate proteoglycans (HSPGs) as high-affinity FGFR 
agonists (2, 3). The splicing of FGFRs results in further distinction of ligand specificity 
accompanied by altered biological properties, in which the most studied splicing isoforms 
involve the third immunoglobulin-like domain of the receptors (4). For FGFR2 and FGFR3, 
the first half of third Ig domain consists of an invariant exon (IIIa), and splicing of the second 
half of third Ig domain results in either IIIb isoform (exons 7 and 8) or IIIc isoform (exons 7 
and 9). Generally, the IIIb isoforms of FGFRs are expressed in tissues of epithelial origin 
whereas the IIIc isoforms are expressed in mesenchymal tissues (5).  
 Binding of FGF/HSPG to FGFR induces the dimerization of receptor monomers in the 
plasma membrane, followed by trans-autophosphorylation of tyrosine residues located in the 
cytoplasmic kinase domain. This tyrosine phosphorylation triggers the binding of Src 
homology (SH2) domain of phospholipase C gamma (PLC) to the receptor, resulting in the 
activation of PKC. Activation also induces RAS-MAPK and PI3K-AKT signaling via FRS2 
and GRB2 adaptor proteins. Additional pathways activated by FGFRs include Jun N-terminal 
kinase and JAK/STAT pathways. FGFR signaling results in cellular proliferation and 
migration, anti-apoptosis, angiogenesis and wound healing (Figure 1) (6). 
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Figure 1. FGFR Signaling Pathways. FGF ligand binds to FGFR monomers, leading to the 
dimerization and subsequent tyrosine autophosphorylation of the receptor. This event leads to 
activaton of FGFRs and various downstream proteins, resulting in cellular proliferation, 
differentiation, survival, anti-apoptosis and angiogenesis. 
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1.2 FGFR TRANSLOCATIONS AND FUSION PROTEINS IN CANCER 
FGFR fusion protein discovery across a variety of cancers 
Fusion proteins are continually being discovered in a variety of human cancers. 
Particularly, fusions involving FGFRs are prevalent in hematological cancers and solid 
tumors. The existence of translocations involving FGFRs has been known since the late 
1990s, when a patient with T-cell lymphoblastic lymphoma was found to harbor a ZNF198-
FGFR1 fusion, now also referred to as ZMYM2-FGFR1. Lymphoma or leukemia cases from 
the 1970s and 1980s described disease characteristics similar to the now well-defined disease, 
8p11 myeloproliferative syndrome (EMS). This correlation may arise because FGFR1 fusions 
in leukemia and lymphoma often originate as EMS. According to the World Health 
Organization, EMS is classified as “myeloid and lymphoid neoplasms with FGFR1 
abnormalities,” and has also been called “stem cell leukemia/lymphoma” (7).  
In EMS, FGFR1 located at 8p11.22 is often disrupted by chromosomal translocation, 
resulting in a fused coding region. The fusions in EMS consistently result in FGFR1 fused to 
an N-terminal dimerization domain (Figure 2), an alteration that has also been found in breast 
cancer, lung squamous cell carcinoma, phosphaturic mesenchymal tumor, rhabdomyosarcoma 
and leukemia (Table 1) (8-11). With FGFR as the 3’ partner, the ligand-binding extracellular 
domain and transmembrane domain are excluded from the fusion protein, with only the FGFR 
kinase domain attached to the 5’ protein partner. Dimerization of this fusion type would result 
only from the N-terminal oligomerization domain, not FGF ligand binding. In solid tumors, it 
is more common to find FGFR as the 5’ fusion gene, with the breakpoint consistently found 
in exons 17, 18, or 19, leaving the extracellular, transmembrane and kinase domains intact. 
When the extracellular domain is present, dimerization is thought to increase with the addition 
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of FGF ligand. Although the domains present in fusion proteins vary, the intact FGFR kinase 
domain is always retained, indicating this domain is critical for a functioning fusion protein 
and cancer progression. It is rare to see an FGFR fusion protein with an additional FGFR 
activating mutation. The reason may be that either event alone may be sufficient for cancer to 
progress, although the dual activation of an FGFR both by mutation and translocation could 
provide additional oncogenic potential. Additionally, while some FGFR fusions occur with 
high tissue specificity, others occur across many cancer types (12). 
 
Dimerization of FGFR induced by the fusion partner  
In FGFR fusion proteins, almost all fusion partners contribute a known dimerization 
domain which allows the FGFR to dimerize and autophosphorylate the kinase domain, 
leading to activation and downstream signaling, increased cell proliferation and cancer 
progression (Figure 1). Recently, an FGFR3 fused to transforming acidic coiled-coil 
containing 3 (TACC3) has been discovered in glioblastoma, bladder cancer, lung cancer, oral 
cancer, head and neck squamous cell carcinoma and gallbladder cancer (8, 9, 13-19) (Table 
1). Additionally, FGFR1-TACC1 has been identified in glioblastoma (18, 20). The coiled-coil 
domain of TACC3 is assumed to bring the FGFR3 portion of the fusion proteins close 
together, inducing activation. FGFR3-TACC3, FGFR3-BAIAP2L1, and FGFR2-CCDC6 
have been shown to dimerize presumably through their coiled-coil domains (8). The FGFR2-
BICC1 gene fusion has been found in cholangiocarcinoma, colorectal cancer and 
hepatocellular carcinoma (8, 21-23). The self-associating sterile alpha motif domain (SAM) of 
BICC1, containing a helix-loop-helix domain, fused 3’ to FGFR2, is believed to instigate 
constitutive dimerization of FGFR2 in order to produce an active receptor (12) (Figure 2).  
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Figure 2. Structural Organization of Select FGFR Fusion Proteins. Schematic representations 
are presented for the more common (n>5) FGFR fusions identified in human cancers and cell 
lines. The most common breakpoint of each fusion is shown. Occurrence numbers (n) indicate 
the total number of times the fusion has been identified, including breakpoints not shown in 
the figure. See Table 3 for full list of FGFR fusions and translocations.  
 
 
Other dimerization domains found in FGFR fusion proteins are believed to have the 
same function. FGFR fusion partner domains include zinc-finger, leucine zipper, coiled-coil, 
SAM, LIS1-homologous (LIsH), IRSp53/MIM (IMD), BAG, FN1, AFF3, and 
stomatin/prohibitin/flotillin/HflK/C (SPFH) domains (also known as the prohibitin PHB 
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domain) (Table 1). Other fusions thought to dimerize by self-association domain include 
FGFR2-CASP7 in breast cancer, which dimerizes through active site loops, and CPSF6-
FGFR1, which dimerizes through a RNA recognition motif (7, 8, 24). The most frequent 
fusion partner domain is the coiled-coil, occurring in the proteins mentioned above; in 
addition, the other coiled-coil fusion proteins are BCR-FGFR1 (25),  CEP110-FGFR1 (7), 
CUX1-FGFR1 (26), FGFR1OP2-FGFR1 (27), FGFR2-AHCYL1 (21), FGFR2-CIT (28), 
FGFR2-FAM76A (29), FGFR2-KIAA1598 (22), FGFR2-KIAA1967 (8), FGFR2-OFD1 (8), 
FGFR2-PPHLN1 (30), FGFR2-TACC3 (23), LRRFIP1-FGFR1 (7), MYO18A-FGFR1 (7), 
TRIM24-FGFR1 (7), and TPR-FGFR1 (31). 
In order for autophosphorylation to occur, RTKs need to be exactly aligned. It has 
been shown that dimerization of the intracellular domain alone will not activate the receptor. 
Ligand binding rotates and aligns the extracellular juxtamembrane domain and 
intramembrane α-helices, leading to intracellular kinase domain alignment, dimerization and 
activation (24). To create an active FGFR fusion protein, the dimerization domain must 
provide the correct alignment. The most common FGFR1 fusion in EMS is ZNF198-FGFR1, 
which contains either 4 or 10 zinc finger domains and a proline-rich domain from ZNF198, 
followed by the tyrosine kinase domain of FGFR1 (Figure 2) (7). The proline-rich domain is a 
self association domain and is essential for dimerization and activation of FGFR1 (32).  
An exception to the activation-by-oligomerization theme is an internal tandem 
duplication (ITD) of FGFR1 in a patient with pilocytic astrocytoma, resulting in a duplication 
of the FGFR1 kinase domain. ITD has previously been observed in Acute Myeloid Leukemia 
with FLT3, another receptor tyrosine kinase. This ITD, which occurs in the juxtamembrane 
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domain of FLT3, leads to enhanced receptor activation and increased downstream signaling of 
MAPK and STAT5 (33).  
 
Altered cellular localization of FGFR by the fusion partner  
Often, the creation of FGFR fusion proteins not only activates FGFR and its canonical 
pathways, but results in an incongruous FGFR localization as well. Some partner proteins can 
lead to localization of FGFR to a cellular compartment other than the plasma membrane. 
Fusion proteins that have been shown to have irregular localization include FGFR1OP-
FGFR1, CEP110-FGFR1, ZNF198-FGFR1, and TEL-FGFR3 in lymphoma and FGFR3-
TACC3 in glioblastoma. Wild-type FGFR1OP (FGFR1 oncogenic partner) and CEP110 
(centriolin) are centrosomal proteins. Once engaged in a fusion with FGFR1, FGFR1OP 
localizes the kinase domain to the centrosome through a CAP350 interaction (34). CEP110 is 
involved in centriole maturation and localizes to the centrosome via an 170-amino acid region 
in the C-terminus, a region retained in the CEP110-FGFR1 fusion. Instead of the expected 
localization to the centrosome, cytoplasmic expression of the fusion protein was observed 
(35). Continuous kinase activity and inappropriate cytoplasmic localization due to CEP110-
FGFR1 fusion formation may result in increased cell viability and hematopoietic stem cell 
growth. The fusion proteins ZNF198-FGFR1 and TEL-FGFR1 have been identified as 
cytoplasmic proteins (7, 11). The translocation of ZNF198 and FGFR1 genes removes the 
FGFR1 transmembrane domain and the C-terminal nuclear localization signal of ZNF198, 
which most likely leads to cytoplasmic localization.  
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Expressed FGFR3-TACC3 has been shown to localize to the mitotic spindle poles in 
dividing mouse astrocytes, most likely due to recruiting effects of TACC3. In addition, the 
fusion protein increased the percentage of aneuploidy by greater than 2.5-fold (18). As 
TACC3 is an important component of mitotic spindle assembly and is involved with the 
attachment of chromosomes to microtubules, it is most likely playing a role in chromosomal 
segregation errors. During mitosis, wild-type TACC3 is strongly diffused around 
centrosomes, due to the localizing effects of the C-terminal coiled-coil (36). As this domain is 
present in the FGFR3 fusion, multiple effects could be implicated by the fusion protein such 
as localization of FGFR3-TACC3 to the centrosome or a novel biochemical activity. During 
interphase, wild-type TACC3 has been found to be concentrated in the nucleus (36). The 
location of the FGFR3-TACC3 fusion in non-dividing cells has not yet been identified.  
Although the localization of ERLIN2-FGFR1 has not yet been investigated, wild-type 
ERLIN2 anchors to the ER membrane via an N-terminal binding motif. This motif is still 
present when ERLIN2 is fused to FGFR1, and may be affecting fusion protein location (37). 
The fusion results in the SPFH oligomerization domain of ERLIN2 fused 5’ to exon 4 of 
FGFR1, and was detected in breast cancer.  
Thus, for these and other FGFR fusion proteins discussed: is the salient biological 
feature the localization of the FGFR kinase domain to a novel cellular compartment? Or, is it 
the constitutive dimerization and activation of the FGFR kinase domain, regardless of the 
localization of the normal fusion partner, that is determinative? Much further experimental 
research will be required to arrive at a definitive answer. 
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Downstream signaling impacts of fusion proteins 
FGFR fusion proteins have been shown to activate the normal FGFR pathways, 
specifically the PI3K/AKT, MAPK, and JAK/STAT pathways (Figure 1). FGFR3-TACC3, 
FGFR3-BAIAP2L1, and FGFR2-CCDC6 increase activation of PI3K/AKT and MAPK 
pathways (12). FGFR2-TACC3 has also been shown to increase MAPK activation, but only a 
moderate increase of FRS2 phosphorylation of the PI3K pathway has been seen (23). In wild-
type FGFR1, FRS2 normally binds to the juxtamembrane domain between amino acids 407 
and 433. In many FGFR1 fusions, this domain is either fully or partially disrupted by 
translocation of the fusion partner, which results in an inability to recruit FRS2. This has been 
shown to occur in ZNF198-FGFR1, but may occur in other fusion proteins with FGFR as the 
3’ partner. However, although FRS2 interaction with ZNF198-FGFR1 was undetectable, the 
PI3K pathway remained active (7).  
In addition to the activation of MAPK and PI3K pathways, cells expressing 
FGFR1OP-FGFR1 exhibit increased phosphorylation of STAT1 and STAT3, but not STAT5 
(38). Furthermore, ZNF198-FGFR1 activates STAT5, FGFR3-TACC3 activates STAT3, and 
FGFR3-BAIAP2L1 and FGFR2-CCDC6 increase STAT1 activation (12, 34). ERLIN2-
FGFR1 and CEP110-FGFR1 have been shown to be biologically active through tyrosine 
phosphorylation of the respective fusion proteins, but further downstream signaling activation 
has not been explored (8, 35). Despite an overall increase in cell proliferation pathway 
activation, a contrasting study reports a failure to over-activate MAPK and AKT by FGFR3-
TACC3 (18). Studies exploring FGFR2-AHCYL1 and FGFR2-BICC1 fusions report an 
absence of AKT and STAT3 phosphorylation, although the MAPK pathway remained active 
(21). Additionally, TEL-FGFR3 directly interacts with and activates STAT3 and STAT5, 
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presumably through the FGFR3 portion of the protein, an interaction that has not been shown 
with other fusion proteins (11).  
Fusions with FGFR as the 5’ partner usually result in a deletion of the last exon of 
FGFR, which includes the tyrosine residue important for PLC binding (39). In bladder 
cancer, cells transfected with FGFR3-TACC3 or FGFR3-BAIAP2L1 were unable to activate 
PLC, due to a deletion of the last exon of FGFR3 in both fusion proteins (14) (Figure 2) 
Chromosomal rearrangements such as these also result in the loss of the 3’ UTR (untranslated 
region) of FGFR, significant as a region that contains various microRNA (miRNA) regulation 
sites. MiR-99a is normally present at high levels in the brain and results in a downregulation 
of FGFR3 translation. The formation of FGFR3-TACC3 fusion in glioblastoma results in a 
loss of the miR-99a site, which leads to the overexpression of FGFR3-TACC3. This miRNA 
site is unique to FGFR3, but overexpression due to a loss of miRNA regulation could occur in 
any FGFR fusion where the 3’ UTR region contains a regulatory miRNA site (17). 
Interestingly, nuclear pore complex proteins have been identified in fusion proteins 
with FGFR1. RANBP2-FGFR1, TPR-FGFR1, and NUP98-FGFR1 have all been identified in 
EMS (7, 31, 40). Mechanistically, these may be similar to other fusion proteins discussed 
previously in that two of these possess dimerization domains, with RANBP2 (RAN binding 
protein 2, also NUP358) containing a leucine zipper domain and TPR (Translocated Promoter 
Region) containing a coiled-coil domain (Table 1). A dimerization motif in NUP98 has not 
yet been identified, however. Also mechanistically unclear is the fusion partner AFF3 
(AF4/FMR2 Family, Member 3, also known as LAF4), a nuclear transcriptional activator, 
which has been identified as the 3’ fusion partner with FGFR2 (Table 1). AFF3 has also been 
found fused to the MLL gene in acute lymphoblastic leukemia (41). It is unclear whether the 
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significant biochemical consequence of these fusion proteins is manifested in the dimerization 
and activation of the FGFR partner, or whether the abnormal nuclear localization of the FGFR 
component represents the key event. 
All EMS cases with FGFR1 fusions have thus far been negative for the BCR-ABL 
fusion gene, which occurs in 85-90% of CML. The remaining cases either contain other 
translocations or are classified as BCR-ABL negative CML, or atypical CML. Some of these 
atypical CML cases are now linked to the broad spectrum of EMS cases, due to the presence 
of a translocation involving the 8p11 region (42). Patients with BCR-FGFR1 
[t(8;22)(p11;q11)] fusion are often referred to as CML-like due to their greater resemblance to 
CML than to EMS. BCR has been shown to interact with Grb2 by phosphorylation of Y177 
(7). This interaction is thought to be important for BCR-ABL signaling in CML patients, and 
may be playing a role in EMS patients with BCR-FGFR1 as well.  
 
Inhibition of FGFR fusion proteins 
Through the use of various drug treatments, a reduction of cell proliferation and FGFR 
fusion protein activity has been accomplished. Studies indicate that an active FGFR kinase 
domain drives cancer progression, thus the goal of many cancer treatments is to inhibit the 
FGFR portion of the fusion (18) (21). FGFR inhibitors have been used in vitro to reduce 
phosphorylation of FGFR and subsequent downstream signaling proteins. FGFR kinase 
inhibitors AZD4547, BGJ398, and PD173074 have inhibited growth of FGFR3-TACC3-
expressing Rat1A and glioma stem-like cells (GSC-1123). PD173074 and AZD4547 both 
resulted in tumor shrinkage during in vivo mouse xenograft studies as well (18). For fusions 
FGFR2-AHCYL1 and FGFR2-BHCC1, both BGJ398 and PD173074 were successful in 
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reducing in vitro fusion activity and cell growth (21). In bladder cancer, sensitivity of FGFR3-
TACC3 and FGFR3-BAIAP2L1 to the kinase inhibitors PD173074, dovitinib, SU5402, and 
BGJ398 has been reported (14). BGJ398 and dovitinib are currently involved in numerous 
clinical trials (clinicaltrials.gov).  
FGFR3 translocations were also targeted using the heat shock protein 90 (HSP90) 
inhibitor, ganetespib (STA-9090). By inhibiting HSP90, hundreds of proteins soon become 
degraded, which disrupts oncogenic signaling pathways. Ganetespib treatment of bladder 
cancer cell line RT112, which contains FGFR3-TACC3, resulted in a decrease of fusion 
protein expression and cell viability. Expression of the apoptosis facilitator protein BIM 
(BCL2-Like 11, or BLC2L11) was induced, indicative of apoptotic pathway activation. 
Combination of ganetespib with BGJ398 proved to be the most effective in causing cell death. 
However, ganetespib had differential effects on protein expression and cell viability in RT4 
and SW780 cell lines, which contain FGFR3-TACC3 and FGFR3-BAI1AP2L1, respectively. 
While HSP90 inhibitors 17-AAG and 17-DMAG reduced cell viability, resistance to 
ganetespib was exhibited. This discrepancy may be due to differences in drug movement or 
metabolism (43). Other HSP90 inhibitory compounds were effective in killing cells 
expressing BCR-ABL in vitro (34). These results collectively indicate the potential of HSP90 
inhibitors against fusion positive cases.  
In cholangiocarcinoma, pazopanib (GW786034B) followed by ponatinib (AP24534) 
treatment, both RTK inhibitors, induced anti-tumor activity in a patient with FGFR2-TACC3. 
Ponatinib treatment also led to anti-tumor activity in a patient exhibiting FGFR2-MGEA5 
fusion. Ponatinib has been FDA approved for treatment of the drug resistant T315I mutation 
in BCR-ABL fusion protein in CML (23).  
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In EMS, the small number of patients who have achieved long term remission have 
received hematopoietic stem cell transplantation. Many therapies used for acute lymphoblastic 
leukemia, acute myeloid leukemia, and myeloproliferative neoplasms have proven 
unsuccessful or display only short term remission against EMS. FGFR1 kinase inhibitor 
SU5402 has shown promise, demonstrating inhibitory effects in cells expressing BCR-FGFR1 
or ZNF198-FGFR1. Interestingly, PI3K, farnesyltransferase, and p38 inhibitors were also 
successful in reducing growth of these cells, whereas MEK inhibitor PD98059 was not (130). 
This is distinct from the MEK inhibitor U0126, which was shown to inhibit growth of cells 
expressing FGFR3-TACC3 (17). While dovitinib has been successful in inhibiting the 
proliferation of Ba/F3 cells transfected with ZNF198-FGFR1 or BCR-FGFR1 and cell lines 
expressing FGFR1OP2-FGFR1, a push for effective FGFR1 inhibitors is needed for EMS 
cases (44). 
 
Translocations leading to FGFR overexpression  
Some translocations do not create a novel fusion protein; rather, these result in 
overexpression of FGFR. In the translocations of SLC45A3-FGFR2 in prostate cancer and 
IgH-MMSET-FGFR3 in Multiple Myeloma (MM), the partner gene promoter now controls 
FGFR transcription, which alters the expression levels of the receptor. SLC45A3-FGFR2 
translocation results in the endogenous promoter and exon 1 noncoding region of SLC45A3 
attached 5’ to the FGFR2 gene, which places FGFR2 transcription under the control of an 
androgen-regulated promoter. This leads to FGFR2 overexpression and oncogenicity (8). 
Multiple Myeloma (MM) is characterized by a growth of malignant cells in the bone 
marrow. In approximately 20% of MM cases, a t(4;14) (p16.3;q32) translocation places 
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MMSET and FGFR3 under the control of the IgH promoter, leading to overexpression of 
FGFR3 (45). The overexpressed FGFR3 often contains an additional mutation, resulting in 
functional changes such as resistance to tyrosine kinase inhibitors (V557M), constitutive 
dimerization (Y375C), or constitutive kinase activation (K652E) (95). However, one third of 
cases with this translocation lose FGFR3 expression while IgH is overexpressed. 
Additionally, although rare, translocations between FGFR3 and an immunoglobulin gene 
enhancer have been found in chronic lymphocytic leukemia (CLL), including t(4;14) 
(p16;q32) between FGFR3 and IgH, and t(4;22) (p16;q11.2) involving FGFR3 and IgL (46, 
47).  
MM cases with the t(4;14) translocation have shown partial responsiveness to the 
FGFR3 inhibitor PD173074 and RTK inhibitor sunitinib (SU-11248). During in vitro studies, 
both inhibitors halted cell growth and inhibited FGFR3 activity, inducing an apoptotic 
response. However, during in vivo studies, tumor growth in the translocation-positive model 
was not inhibited by sunitinib, even though sunitinib was active in the translocation-negative 
tumors. The difference between the in vitro and in vivo data may be due to a difference in 
tumor microenvironment (45). These studies also revealed that RTK inhibitors PD173074, 
sunitinib, and vandetanib (ZD6474) inhibited viability of Ba/F3 cells transformed with 
ZNF198-FGFR1. Sunitinib, which inhibits many RTKs, is approved for metastatic renal cell 
carcinoma treatment (45), and is being examined in clinical trials for relapsed multiple 
myeloma patients. Additionally, masitinib (AB1010, a TK inhibitor) has entered phase II 
clinical trials for MM patients with the t(4;14) translocation. [clinicaltrials.gov]  
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Genomic events that contribute to FGFR fusion proteins  
Although the occurrence of FGFR fusion proteins may be rare, there are similarities 
between fusions. Fusions with FGFR as the 5’ partner have only been found in solid tumors 
so far. In contrast, fusions with FGFR as the 3’ partner have consistently been found in EMS, 
which predisposes patients to either lymphoma, leukemia, or both. A few exceptions have 
been ERLIN2-FGFR1 found in breast cancer (8), BAG4-FGFR1 in lung squamous cell 
carcinoma (LUSC) (8), FOXO1-FGFR1 in rhabdomyosarcoma (48), TEL-FGFR3 in 
lymphoma (11), FN1-FGFR1 in phosphaturic mesenchymal tumor (49), and SQSTM1-
FGFR1 in leukemia (50) (Table 1). 
While the mechanism and cause of gene rearrangements is unknown, both 
intrachromosomal and interchromosomal rearrangements have been identified. 
Rearrangements in the form of tandem duplication, inversion, deletion, or translocation have 
all been identified as FGFR fusion formation events. Translocations occur when two double 
stranded breaks on different chromosomes rearrange and repair (12). Fusion genes joined by a 
translocation can result in the formation of a reciprocal gene (i.e. FGFR2-BICC1 and BICC1-
FGFR2 genes). This has been reported in some cases, such as BCR-FGFR1, CEP110-FGFR1, 
FGFR1OP-FGFR1, FGFR2-AHCYL1, FGFR2-BICC1, HERVK-FGFR1, LRRFIP1-FGFR1, 
RANBP2-FGFR1, SQSTM1-FGFR1, TIF1-FGFR1, and ZNF198-FGFR1 fusions (7, 21-23, 
35, 40, 50, 51). However, reciprocal translocations have not been shown to be translated into 
functional proteins. The majority of these studies do not report the presence of a reciprocal 
fusion gene, and this may be indicative of another genetic alteration, such as an insertion or 
complex rearrangement, which would preclude the formation of the reciprocal gene (7). 
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The formation of these chromosomal rearrangements may occur due to common 
chromosomal fragile sites (CFSs). An increasing number of studies have identified CFSs as 
areas commonly affected by deletions, amplifications, and rearrangements in cancer (52). 
CFSs have become linked to genomic instability, the driving force of cancer. Chromosomal 
breakpoints identified in cancer match to 67% of fragile sites induced in vitro (52). All 
individuals posses CFSs, and these regions have been identified as evolutionarily conserved. 
CFSs contain tandem repeat sequences, often flexible AT-rich repeats and the formation of 
non-B-DNA secondary structures. Additionally, the fragile nature of CFSs has been linked to 
a lack of replicating origins within the CFS region, which may lead to incomplete replication. 
CFS expression is also specific to tissue or cell type. An investigation should be made into the 
correlation between CFS and tumor-specific gene rearrangements, as seen with some FGFR 
fusion protein expression. Mutagens and carcinogens often target CFS regions. Regulation of 
CFS occurs by DNA damage response proteins, including the ataxia telangiectasia mutated 
(ATM) pathway. This pathway is downregulated in cholangiocarcinoma patients with FGFR2 
fusions (30). 
CFS FRA10F has been identified at 10q26, a region which contains the FGFR2 gene 
(23), though some indicate FGFR2 is proximal to FRA10F (52). FGFR2 is also surrounded by 
ribosomal protein pseudogenes (RPS15AP5 and RPL19P16), which contain repetitive bases, 
leading to genomic instability (23). Although not thoroughly investigated, these factors could 
be an indication of the high level of genomic rearrangements seen in the FGFR2 region. In 
this regard, it may be noteworthy that 10 of 107 cholangiocarcinoma patients simultaneously 
exhibited two different fusions, FGFR2-BICC1 and FGFR2-PPHLN1 (30). CFS regions have 
also been identified on the X chromosome, in regions flanking the ODF1 gene, which has 
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been identified in a FGFR2-ODF1 fusion in thyroid cancer (8, 52). As seen (Table 1), FGFR1, 
FGFR2, and FGFR3 rearrangements predominate while, for unknown reasons, FGFR4 
fusions are strikingly absent.  
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1.3 CONCLUDING REMARKS 
Aberrant FGFR signaling, either due to activating mutations or the presence of fusion 
proteins, supports cellular proliferation, tumorigenesis, and cancer progression. Although 
extensive research has shown that targeting FGFRs with small molecule inhibitors halts 
receptor activation, downstream signaling and results in tumor shrinkage, secondary 
mutations that contribute to drug resistance in tumors are challenges to successful clinical 
treatment. In addition, FGFRs fused to dimerizing partners brings a new level of complexity 
in terms of receptor activation and the specificity of small-molecule inhibitors. The 
development of FGFR therapeutics with personalized specificity will advance treatments of 
patients whose tumors harbor activated FGFRs via mutation or fusion protein.  
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CHAPTER 2 
 
Oncogenic Gene Fusion FGFR3-TACC3 Regulated by Tyrosine Phosphorylation 
 
 
 
 
 
ABSTRACT 
 The discovery of translocations and fusion proteins involving Fibroblast Growth 
Factor Receptors (FGFRs) are becoming increasingly common in human cancers. Their 
presence leads to aberrant signaling that contributes to cell proliferation and cancer growth. A 
fusion protein between FGFR3 and transforming acidic coiled-coil containing protein 3 
(TACC3) has become frequently identified in glioblastoma, lung cancer, bladder cancer, oral 
cancer, head and neck squamous cell carcinoma, gallbladder cancer, and cervical cancer. 
Through extensive analysis of the FGFR3-TACC3 fusion protein by titanium dioxide-based 
phosphopeptide enrichment (TiO2)-liquid chromatography (LC)-high mass accuracy tandem 
mass spectrometry (MS/MS), it was demonstrated that the fused coiled-coil TACC3 domain 
results in constitutive phosphorylation of key activating FGFR3 tyrosine residues. The 
presence of the TACC coiled-coil domain leads to increased and altered levels of FGFR3 
activation, fusion protein phosphorylation, MAPK pathway activation, nuclear localization, 
cellular transformation, and IL3-independent proliferation. Introduction of K508R FGFR3 
kinase-dead mutation abrogates these effects, except for nuclear localization which is due 
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solely to the TACC3 domain. These results demonstrate that FGFR3 kinase activity is 
essential for the oncogenic effects of the FGFR3-TACC3 fusion protein and could serve as a 
therapeutic target, but that phosphorylated tyrosine residues within the TACC3-derived 
portion are not critical for activity. 
 
 
2.1 INTRODUCTION 
A subset of the Receptor Tyrosine Kinase (RTK) family is the Fibroblast Growth 
Factor Receptor (FGFR) family, which contains four homologous receptors: FGFR1, FGFR2, 
FGFR3, and FGFR4. FGFR activation results in changes in cellular proliferation and 
migration, anti-apoptosis, angiogenesis, and wound healing. All FGFRs contain three 
immunoglobulin-like (Ig) domains, a transmembrane (TM) domain, and a split tyrosine kinase 
(TK) domain. Binding of Fibroblast Growth Factors (FGFs) and heparin sulfate proteoglycans 
(HSPGs) to the extracellular Ig domains collectively induces FGFR activation through 
dimerization of receptor monomers and trans-autophosphorylation of kinase domain 
activation loop tyrosine residues. Tyrosine phosphorylation of the kinase domain initiates 
activation of RAS-MAPK, PI3K-AKT, and JAK/STAT pathways (1). 
 Mutations in FGFRs have been linked to numerous human cancers and somatic 
disorders, many of which have been extensively studied. More recently, FGFR fusion proteins 
have also begun to emerge in multiple cases of human cancers (1). Since their initial 
discovery in the late 1990s, the detection of these fusion proteins has steadily increased at an 
alarming rate. The focus of this chapter is a fusion protein consisting of FGFR3 fused to 
transforming acidic coiled-coil containing protein 3 (TACC3) that has been identified in 
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glioblastoma, lung cancer, bladder cancer, oral cancer, head and neck squamous cell 
carcinoma, gallbladder cancer, and cervical cancer (1,2). The FGFR3-TACC3 fusion protein 
is a consequence of a 70 kb tandem duplication at 4p16.3 (3). This causes a reversal of the 
two genes, as TACC3 is normally upstream of FGFR3. TACC3 is a member of the TACC 
family, which consists of 3 known human proteins, TACC1, TACC2, and TACC3, all of 
which are involved in key roles of microtubule organization during mitosis. TACC3 is 
believed to be essential for the stabilization of kinetochore fibers and the mitotic spindle.  A 
particularly important domain of this family is the C-terminal coiled coil domain (named 
TACC domain), which is highly conserved in all family members. This domain is believed to 
play an important role in localization of the protein during mitosis (4).  
The frequent occurrence of this fusion protein across many cancer types leads to the 
question of how this protein is contributing to cancer progression. Is FGFR3 becoming 
constitutively activated due to the presence of the TACC domain? Is the presence of the 
coiled-coil domain able to stimulate activation loop phosphorylation in the FGFR3 kinase 
domain? Does the TACC3 domain play an important role in advancing cancer progression, or 
is its key role to activate the tyrosine kinase? While studies have investigated FGFR3 and 
TACC3 as separate entities, little has been defined about the FGFR3-TACC3 fusion protein. 
This chapter investigates various properties of this fusion protein and its contribution to 
cancer progression, including mass spectrometry analysis of phosphorylation of key tyrosine 
residues, downstream signaling, cell transformation, and localization. 
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2.2 RESULTS 
Constitutive phosphorylation of FGFR3-TACC3 fusion protein 
In the FGFR3-TACC3 fusion protein, tyrosine kinase domain dimerization and 
autophosphorylation may be elevated by the presence of the TACC3 coiled coil domain, 
which could be crucial to cancer progression. To investigate changes in phosphorylation and 
biological activity, various FGFR3-TACC3 DNA derivatives were constructed. All fusion 
constructs contain the breakpoint between exon 18 of FGFR3 to exon 11 of TACC3 as shown 
in Figure 3, chosen due to the high occurrence of this particular fusion breakpoint (3,5). This 
fusion is predicted to contain the extracellular, transmembrane, and intracellular kinase 
domains of FGFR3 fused 5’ to the coiled-coil domain of TACC3 (6). Constitutively activated 
FGFR3 clones were produced by the K650E mutation. This mutation is known to cause 
Thanatophoric Dysplasia type II (TDII), a lethal form of achondroplasia, and is a highly 
activating and pathogenic FGFR3 mutation (1). The kinase activity of FGFR3 was abrogated 
by K508 to R mutation, known as the “kinase-dead” (KD) mutant (Figure 3A). 
To examine the phosphorylation of each fusion construct compared to FGFR3 WT, 
FGFR3(K650E), and FGFR3(K508R), constructs were expressed in HEK293 cells, collected 
and immunoprecipitated with an N-terminal FGFR3 antibody (Figure 3B, top panel). An 
increase in tyrosine phosphorylation was seen in FGFR3-TACC3 compared to FGFR3 WT 
(lanes 2 and 6). No phosphorylation signal could be detected for the kinase-dead FGFR3 with 
or without the fused TACC3 (Figure 3B). These results show that tyrosine phosphorylation of 
the fusion protein was increased by the presence of dimerizing TACC3 coiled coil and can be 
amplified by the presence of the activating K650E mutation. Quantitation of phosphorylation 
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levels shows a 2-fold increase in tyrosine phsophorylation on the FGFR3-TACC3 fusion 
protein compared to FGFR3 WT (Figure 3C).  
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Figure 3. Increase in tyrosine phosphorylation by introduction of the TACC domain. (A) 
Schematic of FGFR3-TACC3 fusion protein. The N-terminal extracellular ligand-binding 
domain, transmembrane (TM), kinase, and kinase insert (KI) domains of FGFR3 are followed 
by a 3 amino acid linker (residues ASM), and fused to TACC3 starting at exon 11, which 
contains a coiled-coil domain. The location of K508 and K650 are shown. (B) Various 
mutation and fusions with FGFR3 were expressed in HEK293 cells, immunoprecipitated with 
FGFR3 antibody, and immunoblotted with phosphotyrosine antibody (top panel). Expression 
of the constructs were visualized in the lysates by immunoblotting with FGFR3 antisera 
(middle panel) and TACC3 antisera (bottom panel). (C) Quantification of tyrosine 
phosphorylation showing the standard error of the mean for 3 independent repeats, normalized 
to FGFR3(K650E). 
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LC-MS/MS analysis identifies elevated and novel phosphorylation sites  
The strong increase in tyrosine phosphorylation seen by Western blot led to the 
question of whether TACC3 leads to a constitutively phosphorylated FGFR3 kinase and if 
additional or novel phosphorylation sites exist on the fusion protein. In order to explore this 
possibility, titanium dioxide-based phosphopeptide enrichment (TiO2)-liquid chromatography 
(LC)-high mass accuracy tandem mass spectrometry (MS/MS) was used with samples from 
HEK293T cells expressing FGFR3 or FGFR3-TACC3 derivatives to identify significant 
phosphorylation sites. Immunoprecipitation with the FGFR3 N-terminal antibody and on-bead 
tryptic digestion revealed strong FGFR3 activation loop phosphorylation at residues Y647 and 
Y648 in both fusion proteins and non-fused FGFR3 and FGFR3(K650E) (Figure 4B), 
indicating the receptor was constitutively active in all samples. Mass spectrometry analysis 
performed on the FGFR3 (K508R) derivatives detected no phosphorylated tyrosine residues 
(data not shown). All tyrosine phosphorylation sites detected on the fusion protein are 
indicated in Figure 4C.  
By comparing non-fused FGFR3 to FGFR3-TACC3, the effect of the coiled-coil 
domain on receptor phosphorylation and activation can be seen (Figure 4A, 4B). Not only are 
phosphorylation levels more robust, but additional phosphorylation sites can be detected in 
the FGFR3 portion of the fusion, such as Y577, Y599, and Y607 (Figure 4B, 1st and 3rd 
panels), indicating that receptor phosphorylation is over-stimulated in a ligand independent 
manner due to the presence of the TACC domain. The presence of the activating mutation 
K650E in FGFR3-TACC3 shows that the presence of the TACC domain leads to higher 
phosphorylation intensity levels of the receptor (Figure 4A, 2nd and 4th panels).  
  
36 
 
 
Figure 4. Phosphorylated tyrosine residues in FGFR3, FGFR3(K650E), FGFR3-TACC3, and 
FGFR3(K650E)-TACC3 identified by mass spectrometry analysis. (A) The intensity of the 
phosphotyrosine residues detected are presented normalized to 2 phosphoserine residues 
(S424 and S444) which were found to be constitutively phosphorylated across all samples. 
Duplicate, independent samples were subjected to mass spectrometry analysis. (B) For each 
phosphotyrosine residue detected, the percentage of intensity within the total protein is 
presented. (C) Schematic of FGFR3-TACC3 with the location of all tyrosine phosphorylation 
sites identified by LC-MS/MS.  
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Representative phosphorylated spectra are shown in Figure 5. A commonly identified 
FGFR3 WT peptide containing double phosphorylation of Y647 and Y648 in the activation 
loop is shown in panel A. In FGFR3-TACC3 fusion protein constructs, this double 
phosphorylated peptide becomes less frequent, with detection of peptides containing single 
Y647 phosphorylation becoming more common (Figure 4, 5B, 7C). Also shown are spectra 
containing primary phosphorylation sites Y577, Y798, and Y867 in FGFR3-TACC3 and 
FGFR3(K650E)-TACC3 (Figure 5D, 5E, 5F).  
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Figure 5. Representative spectra of selected peptides. The relative intensity of select ions of 
major phosphorylation sites are shown. Due to space constraints, not all identified ions are 
labeled. Identification of samples are as follows: (A) FGFR3 WT (B) FGFR3-TACC3 (C) 
FGFR3(K650E)-TACC3 (D) FGFR3-TACC3 (E) FGFR3-TACC3 (F) FGFR3(K650E)-
TACC3. 
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There are four tyrosine residues in the TACC3 portion of the FGFR3-TACC3 fusion 
protein: Y798, Y853, Y867, and Y878, corresponding to residues Y684, Y739, Y753, and 
Y764 in TACC3 WT. In FGFR3-TACC3, it was previously unknown if these tyrosine 
residues were also phosphorylated, possibly by the fused kinase domain, and if they play a 
role in cancer development. Through MS analysis, phosphorylation sites Y798, Y853, and 
Y867 were identified in FGFR3-TACC3 (Figure 4C). Due to tryptic digest peptide size, Y853 
was only recovered by a peptide miscleavage and Y878 was unable to be recovered. 
Increasing receptor activation by K650E mutation led to an increase in intensity levels of 
TACC3 tyrosine phosphorylation (Figure 4A, 3rd and 4th panels).  
Of the phosphorylation sites detected in the TACC3 portion of the fusion protein, 
Y798 and Y853 have been previously identified as a phosphorylation sites in TACC3 WT. 
The function of these sites is unclear and these residues are not conserved in the TACC family 
(7,8). However, Y867 is a conserved tyrosine residue in the TACC family and our data has 
identified it as a novel phosphorylation site for the FGFR3(K650E)-TACC3 fusion protein.  
As mentioned above, mass spectroscopy of HEK293T cells expressing 
FGFR3(K508R)-TACC3 (kinase dead mutation) revealed no phosphorylated peptides within 
the FGFR3 or TACC3 domains. This indicates that receptor activation is required for tyrosine 
phosphorylation of the fusion proteins, and the TACC domain is most likely phosphorylated 
by the FGFR3 kinase domain, not another tyrosine kinase.  
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Cell transforming ability of FGFR3-TACC3 by focus assay  
To examine the transforming activity of FGFR3-TACC3 and subsequent mutants, 
focus-forming assays with NIH3T3 cells were performed. FGFR3-TACC3 and 
FGFR3(K650E)-TACC3 produced extremely high foci formation and cell transformation 
compared to FGFR3 WT or FGFR3(K650E) (Figure 6). Expression of PR/neu*, a focus assay 
positive control, displayed less transformation than FGFR3-TACC3, the latter of which also 
consistently produced much larger foci. PR/neu* is a Platelet-Derived Growth Factor 
Receptor, Beta (PDGFR-β) with a Neu receptor transmembrane domain with the activating 
V664E mutation (p185
neu*
) (9). Despite the previously demonstrated elevated activation of 
PR/neu*, its transforming ability was dwarfed by the foci formation seen by FGFR3(K650E)-
TACC3. As a result, samples were normalized to FGFR3(K650E)-TACC3 (Figure 6). 
Expression of FGFR3(K508R)-TACC3 (kinase-dead mutation) and TACC3 WT in NIH3T3 
cells did not produce significant foci formation, indicating that an active FGFR3 kinase 
domain is essential for cell transforming ability of FGFR3-TACC3.  
Within the coiled-coil domain in FGFR3-TACC3, there are four tyrosine residues. 
Three of these residues were found to be phosphorylated by MS analysis, as discussed above, 
and the fourth tyrosine, Y878, undetectable by trypic digest, is believed to be phosphorylated 
as well (10). In order to assess the importance of these FGFR3-TACC3 phosphorylation sites, 
all four TACC3 tyrosine residues were mutated to phenylalanine (Y798F, Y853F, Y867F, 
Y878F) with and without the activating FGFR3 K650E mutation by site-directed mutagenesis 
and analyzed for  focus forming ability. NIH3T3 cells expressing the fusion constructs with 
all four tyrosine mutations, FGFR3-TACC3 4xYF and FGFR3(K650E)-TACC3 4xYF, 
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displayed high foci formation when compared to FGFR3-TACC3 or FGFR3(K650E)-TACC3 
with no additional mutations (Figure 6).  
 
 
Figure 6. Transformation of NIH3T3 cells by FGFR3 and FGFR3-TACC3 derivatives. 
Representative plates from a focus assay are shown, with transfected constructs indicated. 
Number of foci were scored, normalized by transfection efficiency, and quantitated relative to 
FGFR3(K650E)-TACC3 +/- standard error of the mean. PR/neu* is a positive control. Assays 
were performed a minimum of three times per DNA construct. 
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To assess the effects of each individual phosphorylation site, single Y to F mutants 
were made in combination with activating mutation K650E. As shown in Figure 6, three of 
the mutations (Y853F, Y867F, Y878F) increased foci formation at an even higher rate than 
K650E mutation alone, indicating an inhibitory role on cell growth when phosphorylated in 
the FGFR3-TACC3 fusion. An exception may be FGFR3(K650E)-TACC3(Y798F), which 
displayed a slightly lower transformation ability than FGFR3(K650E)-TACC3, indicating this 
phosphorylation site may be important to cell proliferation.  
 
FGFR3-TACC3 promotes IL-3 independent cell growth 
The transforming potential of select fusion proteins was also examined in the murine 
myeloid cell line 32D which is dependent on Interluekin-3 (IL-3) for growth (11-13). FGFR3 
WT, FGFR3-TACC3, FGFR3(K650E), FGFR3(K650E)-TACC3, FGFR3-TACC3(4xYF) and 
PR/neu* were electroporated into the 32D cell line and selected as described in the Materials 
and Methods. As seen in Figure 7A, in the absence of IL-3 all the clones expressed were able 
to lead to IL-3 independent growth indicating their transforming potential. Interestingly, the 
FGFR3-TACC3(4xYF) clone had the highest proliferation even without the activating K650E 
mutation. This could support the suggestion of the TACC3 tyrosine residues as being 
inhibitory. In addition, even in the presence of IL-3 (Figure 7B) the expression some of the 
clones enhanced the proliferation of the 32D cells compared to nonexpressing cells. The 
viability assays performed on days 3 and 7 shown in Figure 7C support the cell population 
assay results. All transfected constructs display cell viability, whereas 32D control cells do 
not, indicating that FGFR3-TACC3 and other constructs promote cell proliferation. 
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Figure 7. IL-3 independent growth and MTT viability assay in 32D cells expressing FGFR3 
or FGFR3-TACC3 derivatives. PR/neu* is a positive control. (A) 32D cells selectively 
expressing FGFR3, FGFR3-TACC3, FGFR3(K650E), FGFR3(K650E)-TACC3, FGFR3-
TACC3(4xYF), or PR/neu* were cultered in the absence of IL-3. The total number of viable 
cells were determined by trypan blue exclusion. Experiments were performed in triplicate, 
standard deviation is shown. (B) Cell counts of cultures in (A) in the presence of IL-3. 
Experiments were performed in triplicate, standard deviation is shown. Inset of growth from 
(A) without IL-3 is shown for comparison. (C) Cell viability as determined by MTT assay by 
3 independent repeats on days 3 and 7. Relative absorbance was obtained by ratio of –IL-3 to 
+IL-3 absorbances read at 570 nm. Standard deviation is shown.  
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FGFR3-TACC3 displays nuclear localization 
The presence of TACC3, a nuclear localizing protein (4), led to the question of 
whether a delocalization of the over activated FGFR3 kinase to the nucleus was occurring. 
Indeed, fractionation of MCF7 cells expressing FGFR3 WT, FGFR3(K650E), 
FGFR3(K508R), and their fusion counterparts displayed a clear difference in localization 
(Figure 8A). All three fusions, FGFR3-TACC3, FGFR3(K650E)-TACC3, FGFR3(K508R)-
TACC3 (nuclear fraction, lanes 5, 6 & 7) displayed strong nuclear localization. The non-fused 
tyrosine kinase domains (lanes 2, 3 & 4) were present mainly in the cytoplasmic fraction. 
Perinuclear localization of FGFR3(K650E) has been demonstrated previously (14), but fusion 
of FGFR3(K650E) to TACC3 dramatically increased nuclear localization. These results 
indicate the presence of the TACC3 coiled coil domain is responsible for nuclear localization 
of the FGFR3 kinase, regardless of receptor activation. Immunoblotting for nuclear localizing 
mSin3A and cytoplasmic β-tubulin confirmed separation of nuclear and cytoplasmic 
fractions.  
 
Downstream signaling activation by FGFR3-TACC3 
 It has been shown previously that FGFR3 WT and FGFR3(K650E) activate the signal 
transducer and activator of transcription (STAT) pathway and mitogen activated protein 
kinase (MAPK) pathway, but it is not clear how this activation compares to our constructed 
FGFR3-TACC3 or FGFR3(K650E)-TACC3 fusions. HEK293 cells expressing these fusions 
and their non-fused counterparts were analyzed for STAT1 and STAT3 activation. Both 
FGFR3(K650E) and FGFR3(K650E)-TACC3 led to phosphorylation of STAT1 and STAT3, 
but a significant increase in phosphorylation was not seen for the fusion constructs (Figure 
  
45 
8B). However, MAPK phosphorylation was strongly elevated by FGFR3-TACC3 and 
FGFR3(K650E)-TACC3 (Figure 8C, lanes 6 & 7), compared to non-fused FGFR3 WT and 
FGFR3(K650E) (lanes 2 & 3), indicating that FGFR3-TACC3 induces MAPK pathway 
activation. The kinase-dead FGFR3(K508R)-TACC3 did not display this activation (lane 8), 
indicating that FGFR3 kinase activity in the fusion protein is essential to downstream 
signaling activation.  
 
Figure 8. Localization and signaling of FGFR3-TACC3 fusions. (A) Fractionation of MCF7 
cells expressing FGFR3 or FGFR3-TACC3 derivatives. Cells were separated into cytoplasmic 
(left) and nuclear (right) fractions. Immunoblotting with FGFR3 antibody shows nuclear 
localization of FGFR3-TACC3 fusions (top panels). Immunoblotting for mSin3A and β-
Tubulin confirm fractionation (2nd and 3rd panels). (B) Lysates of HEK293 cells expressing 
FGFR3 or FGFR3-TACC3 derivatives were immunoblotted for Phospho-STAT1 (Y701) 
(top), STAT1 (2nd panel),
 
Phospho-STAT3 (Y705) (3rd panel), STAT3 (4th panel), and 
FGFR3 (bottom). (C) HEK293 cell lysates expressing FGFR3 or FGFR3-TACC3 derivatives 
were immunoblotted for Phospho-MAPK (T202/Y204) (top), MAPK (2nd panel), and FGFR3 
(bottom).  
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2.3 DISCUSSION 
 We extensively analyzed the FGFR3-TACC3 fusion protein by tyrosine residue 
phosphorylation changes and the impacts on cancer progression. We demonstrate that 
introduction of a 3’ TACC3 coiled-coil domain results in constitutive activation and 
phosphorylation of key residues in FGFR3. Clearly, the TACC domain over-stimulates kinase 
activity, as shown by the additional phosphorylation sites detected by LC-MS/MS. Activation 
by this coiled coil domain has a more severe impact on cell transformation and downstream 
signaling than the activating K650E mutation alone, which causes the lethal syndrome 
Thanatophoric Dysplasia type II. By focus, proliferation, and viability assay, the high cell 
transformation, proliferation, and oncogenic potential of the fusion protein was demonstrated. 
The absence of biological activity shown by FGFR3(K508R)-TACC3 kinase dead mutant 
indicates that kinase activity is required for gain of function and cancer progression, but not 
required for nuclear localization of the fusion protein, as shown by cellular fractionation.  
 Examining the nonfused FGFR3 proteins, the analysis by LCMS/MS indicates key 
FGFR3 residues are being phosphorylated, primarily residues Y647 and Y648 as part of the 
YYKK activation loop motif essential to FGFR kinase activity (15). In the fusion protein 
FGFR3-TACC3, Y647 was the major site of phosphorylation within the activation loop, and 
phosphorylation of additional sites such as Y577, Y599, Y607, Y724, and Y798 was also 
observed. Introduction of the K650E mutation into the fusion protein FGFR3(K650E)-
TACC3 resulted in increased phosphorylation of all the sites seen in the FGFR3-(K650E) as 
well as the sites seen in the FGFR3-TACC3 sample, with the additional appearance of 
phosphorylation at Y867 in the TACC3 domain. Residue Y724 has been shown to be critical 
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for activation of downstream signaling pathways, such as MAPK, STAT, and PI3K, and cell 
transformation (16). 
 Although the function has not been thoroughly explored for all the phosphotyrosine 
sites detected by MS analysis (Figure 4C), all sites are highly conserved in the four FGFRs, 
with the exception of Y577 which is not conserved in FGFR4. Interestingly, it has been 
suggested that Y577 is a key residue for the activation of FGFR3(K650E). Upon 
phosphorylation at Y577 the active state confirmation of the receptor is stabilized, 
independent of activation loop phosphorylation (17). The strong peak intensity seen for Y577 
in FGFR3-TACC3 could indicate a change in the mechanism of activation in a ligand 
independent manner due to the TACC domain (Figure 6B). 
 The fusion breakpoint of exon 18 in FGFR3 excludes the binding site for PLCγ 
(Y760), thus PLCγ is no longer recruited by FGFR3-TACC3, as previously shown (5). 
Additionally, Y760 may contribute to maximal STAT activation (16). The removal of this site 
from FGFR3-TACC3 may be contributing to the absence of STAT pathway overactivation. 
However, significant increase of downstream signaling activation was seen in the MAPK 
pathway independent of FGF ligand stimulation, which correlates with previous findings and 
further indicates ligand-independent activation and cell growth (3,5,18).  
Overexpression of TACC3 WT has been shown to increase activation of MAPK 
signaling pathway and contribute to the epithelial-mesenchymal transition (EMT) (19). 
However, we found that overexpression of TACC3 alone does not lead to increased MAPK 
activity (HEK293) or cell transformation (NIH3T3). Our results indicate that the fusion of 
FGFR3 and TACC3 is required for gain of oncogenic function.  
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Also missing from the FGFR3-TACC3 fusion breakpoint is the Aurora-A 
phosphorylation sites on TACC3. Aurora-A has been shown to phosphorylate TACC3 WT at 
S558 which is required for the localization of a TACC3-chTOG-clathrin complex to mitotic 
spindle microtubules and spindle poles (6,20,21). Localization of TACC3 to kinetochore 
fibers in complex with chTOG and clathrin is believed to assist with stabilization and 
formation of the mitotic spindle (21). However, previous studies have found the FGFR3-
TACC3 fusion protein localized only to the mitotic spindle poles during mitosis, and 
relocated during late stage mitosis to the midbody. A mechanism for this change in 
recruitment and the role of FGFR3-TACC3 during interphase remains unclear (22).  
Although not analyzed in regards to the cell cycle, we show a strong indication of 
nuclear localization for the fusion protein. Additionally, localization of FGFR3-TACC3 to the 
nucleus is not dependent on kinase activity as shown by K508R mutation, indicating that this 
localization is solely due to the fused TACC domain. Since the Aurora A phosphorylation 
sites are no longer present in the fusion protein, there must be another nuclear recruitment 
mechanism occurring. This delocalized kinase could be interacting with novel proteins that 
lead to cancer progression. 
The detection of phosphorylated TACC3 residues (Y798, Y853 and Y867 
corresponding to Y684, Y739, and Y753 in native TACC3) could indicate the ability of a 
highly activated FGFR3 kinase to self-phosphorylate the TACC domain and potentially lead 
to increased downstream signaling. Phosphorylation of Y878 was unable to be recovered by 
MS, but is presumably phosphorylated as it is located in a conserved 9 amino acid tyrosine 
phosphorylation motif within the TACC family (10). Our results, in which mutation to 
phenylalanine of all four tyrosine residues within the TACC3 domain leads to increased focus 
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formation and IL3-independent cell proliferation, leads to the conclusion that phosphorylation 
at these sites, while it does occur, fails to contribute significantly to the oncogenic potential of 
the FGFR3-TACC3 fusion oncogene. 
Recently, it has been shown that chTOG (colonic and hepatic tumor overexpressed 
gene), a centrosomal localizing protein, recruits TACC3 to microtubule plus-ends during 
interphase. This localization is dependent on chTOG, not TACC3, and is independent of 
Aurora A phosphorylation (21). TACC3 residues 672-688 contain the binding site of ch-TOG 
and are present in the FGFR3-TACC3 fusion protein (at residues 786-802). Within this region 
is Y798, which we have found to be highly phosphorylated in the FGFR3-TACC3 and 
FGFR3(K650E)-TACC3 fusion proteins by LC-MS/MS. In the K650E background, when the 
phosphorylation site is removed by mutation Y798F, we did not observe a significant change 
in biologic activity, suggesting that the specific phosphorylation of Y798 occurs 
adventitiously and is extrinsic to the biological properties of the FGFR3-TACC3 fusion..  
Introduction of Tyr-to-Phe mutations at all of the retained TACC3-derived residues 
Y798, Y853, Y867, or Y878 resulted in changes in biologic activity that were statistically 
insignificant, again indicating that the phosphorylation we observed at these sites is 
biologically inconsequential. An inhibitory phosphorylation site has been shown to occur in 
FGFR3 WT at Y770 which, upon phosphorylation, inhibits cell transformation (16). Residue 
Y770 has been removed from the FGFR3-TACC3 fusion, but the significance of this change 
was not explored here. 
We have presented overwhelming evidence of the high oncogenicity of the FGFR3-
TACC3 fusion protein. The presence of the TACC coiled-coil domain leads to increased and 
altered levels of FGFR3 activation, fusion protein phosphorylation, downstream signaling, 
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and cellular transformation, proliferation, and viability. The existence of FGFR3-TACC3 
fusions in human cancers creates additional challenges and opportunities for identifying 
effective treatment strategies. Further study of novel pathways activated by the FGFR3-
TACC3 fusion protein, and a deeper understanding of the molecular details exploited by 
FGFR3-TACC3 to achieve its biologic potency, can be expected lead to novel therapeutic 
paradigms. 
 
 
2.4 MATERIALS AND METHODS 
DNA constructs 
 The TACC3 gene was purchased from Sino Biological Inc (pMD-TACC3) and was 
subcloned into pcDNA3. FGFR3, FGFR3(K650E), and FGFR3(K508R) were developed as 
previously described (23). To construct FGFR3-TACC3 fusion gene a unique ClaI site was 
introduced by PCR based site directed mutagenesis after residue 758 in FGFR3 and before 
residue 648 in TACC3. This unique site was used to subclone TACC3 3’ of FGFR3 in 
pcDNA3, creating a fusion breakpoint of FGFR3 exon 18 to TACC3 exon 11 with a 3 amino 
acid linker of residues ASM containing the ClaI site.  
Fragments containing K650E or K508R mutations were subcloned into the FGFR3-
TACC3 fusion gene. Single and multiple tyrosine mutations in the TACC3 region (Y798F, 
Y853F, Y867F, Y878F) were introduced by PCR based site directed mutagenesis. DNA 
constructs were then subcloned into pLXSN vector (24) for focus, proliferation, and MTT 
assays. All clones were confirmed by DNA sequencing.  
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Cell culture  
HEK293, HEK293T, and NIH3T3 cells were maintained in DMEM plus 10% fetal 
bovine serum (FBS) and 1% penicillin/streptomycin in 10% CO2, 37°C. MCF7 cells were 
maintained at 5% CO2 in DMEM plus 10% FBS and 1% penicillin/streptomycin in 37°C. 
32D clone 3 (ATCC CRL-11346) cells were maintained in RPMI 1640 medium with 10% 
FBS, 1% penicillin/streptomycin, and 5 ng/mL mouse IL-3 in 5% CO2 37°C.  
 
Mass Spectrometry Sample Preparation 
HEK293T cells were plated one day prior to transfection at 3.0 x 10
6 
cells per 15-cm 
tissue culture plate. 10 plates per sample were transfected by calcium phosphate precipitation 
with 9μg of FGFR3 or FGFR3-TACC3 derivatives. After 18-20 hr, cells were treated with 10 
μM MG132 for 4-6 hr, washed once in 1xPBS + 1mM Na3VO4 before being lysed in RIPA. 
Clarified lysates were immunoprecipitated with FGFR3 antisera overnight at 4°C with 
rocking. Immune complexes were collected with Pierce protein A/G magnetic beads as per 
manufactures directions. Samples were taken to The Sanford Burnham Prebys Medical 
Discovery Institute mass spectrometry facility for proteasome on bead digestion and liquid 
chromatography (LC)-high mass accuracy tandem mass spectrometry (MS/MS) analysis.  
Following immunoprecipitation, proteins were digested directly on-beads using 
Trypsin/Lys-C mix. Briefly, the samples (IP’s and controls) were washed with 50 mM 
ammonium bicarbonate, and then resuspended with 8M urea, 50 mM ammonium bicarbonate, 
and cysteine disulfide bonds were reduced with 10 mM tris(2-carboxyethyl)phosphine 
(TCEP) at 30°C for 60 min followed by cysteine alkylation with 30 mM iodoacetamide (IAA) 
in the dark at room temperature for 30 min. Following alkylation, urea was diluted to 1 M 
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urea using 50 mM ammonium bicarbonate. The samples were finally subjected to overnight 
digestion with mass spec grade Trypsin/Lys-C mix (Promega, Madison, WI). Finally, peptides 
were collected into a new tube, and the magnetic beads were washed once with 50mM 
ammonium bicarbonate to increase peptide recovery. The digested samples were partially 
dried to approximately 50% of the total volume, and desalted using a C18 TopTip (PolyLC) 
according to the manufacturer’s recommendations. The desalted peptide sample was split into 
2 aliquots, ‘Total’ and ‘Phospho’ containing 10% and 90% of the sample, respectively. Both 
aliquots were then dried using a SpeedVac system.   
The ‘Phospho’ aliquot was resuspended in 80% acetonitrile, 5% trifluoroacetic acid in 
1M glycolic acid and incubated with TiO2 magnetic beads (GE) for 30 min in a Thermomix at 
room temperature and 900 rpm. The unbound peptides were removed and the magnetic beads 
were washed twice with 80% acetonitrile, 5% trifluoroacetic acid to remove non-
phosphorylated peptides. Finally, phosphopeptides were eluted with 5% ammonium 
hydroxide and dried down using a SpeedVac system. 
 
LC-MS/MS Analysis 
Both the ‘Total’ and ‘Phospho’ were analyzed by LC-MS/MS. Fifty percent of each 
sample was used for LC-MS/MS, a 0.180 x 20 mm C18 trap Symmetry column (Waters corp., 
Milford, MA) connected to an analytical C18 BEH130 PicoChip column 0.075 x 100 mm, 
1.7μm particles (NewObjective, MA) mounted on a nanoACQUITY Ultra Performance 
Liquid Chromatography system (Waters corp., Milford, MA), directly coupled to an Orbitrap 
Velos Pro mass spectrometer (Thermo Fisher Scientific). The peptides were separated with a 
90-min non-linear gradient of 2-35% solvent B at a flow rate of 400nL/min. The mass 
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spectrometer was operated in positive data-dependent acquisition mode. MS1 spectra were 
measured with a resolution of 60,000, an AGC target of 10
6
 and a mass range from 350 to 
1400 m/z. Up to 5 MS2 spectra per duty cycle were triggered, and each precursor was 
fragmented twice by collisium-induced dissociation (with multiple stage activation enabled) 
and electron transfer dissociation (ETD), and acquired in the ion trap with an AGC target of 
10
4
, an isolation window of 2.0 m/z and a normalized collision energy of 35. Dynamic 
exclusion was set to 5 seconds to allow multiple fragmentation of phosphopeptides. 
 
Proteomics data analysis 
All mass spectra from were analyzed with MaxQuant software version 1.5.2.8 (Cox et 
al). Briefly, MS/MS spectra were searched against the cRAP protein sequence database 
(http://www.thegpm.org/crap/) indexed with corresponding FGFR3 or FGFR3-TACC3 
derivative sequences. Precursor mass tolerance was set to 20ppm and 4.5ppm for the first 
search where initial mass recalibration was completed and for the main search, respectively. 
Product ions were searched with a mass tolerance 0.5 Da. The maximum precursor ion charge 
state used for searching was 7. Carbamidomethylation of cysteines was searched as a fixed 
modification, while phosphorylation of serines, threonines and tyrosines, and oxidation of 
methionines was searched as variable modifications. Enzyme was set to trypsin in specific 
mode and a maximum of two missed cleavages was allowed for searching. The target-decoy-
based false discovery rate (FDR) filter for spectrum and protein identification was set to 1%. 
Second peptide mode of MaxQuant software was also enabled.  
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Antibodies and Reagents 
Antibodies were obtained from the following sources: FGFR3 (B-9), mSin3A (K-20), 
β-tubulin (H-235), STAT1 (E-23), STAT3 (C-20) from Santa Cruz Biotechnology; 
phosphotyrosine (4G10) from Millipore; TACC3 C-terminal (SAB4500103) from Sigma; 
Phospho-STAT1 (Tyr701) (9171), Phospho-STAT3 (Tyr705) (D3A7), Phospho-p44/42 
MAPK (Erk1/2) (T202/Y204) (E10), p44/42 MAPK (Erk1/2) (9102) from Cell Signaling 
Technology; horseradish peroxidase (HRP) anti-mouse, HPR anti-rabbit from GE Healthcare. 
Enhanced chemiluminence (ECL and Prime-ECL) reagents were from GE Healthcare. 
MG132, aFGF, and recombinant mouse Interleukin-3 (IL-3) were obtained from R&D 
systems; Heparin was from Sigma; Geneticin (G418) was from Gibco. Lipofectamine 2000 
Reagent was from Invitrogen.  
 
Transfection, Immunoprecipitation, Immunoblot 
 HEK293 were plated at a density of 1 x 10
6
 cells/100-mm plate and transfected with 3 
μg plasmid DNA using calcium phosphate transfection in 3% CO2 as previously described 
(25). 20 to 24 hr after transfection, media was changed to DMEM with 0% FBS. Cells were 
starved for 20 hr before collecting and lysis. 
Transfected HEK293 cells were collected, washed once in PBS, and lysed in 1% NP40 
Lysis Buffer [20 mmol/L Tris-HCl (pH 7.5), 137 mmol/L NaCl, 1% Nonidet P-40, 5 mmol/L 
EDTA, 50 mmol/L NaF, 1 mmol/L sodium orthovanadate, 1 mmol/L phenylmethylsulfonyl 
fluoride (PMSF), and 10 μg/mL aprotinin] or radioimmunoprecipitation assay buffer [RIPA; 
50 mmol/L Tris-HCl (pH 8.0), 150 mmol/L NaCl, 1% TritionX-100, 0.5% sodium 
deoxycholate, 0.1% SDS, 50 mmol/L NaF, 1 mmol/L sodium orthovanadate, 1 mmol/L 
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PMSF, and 10 μg/mL aprotinin]. Bradford assay or Lowry assay was used to measure total 
protein concentration. Antibodies were added to lysates for overnight incubation at 4°C with 
rocking, followed by immunoprecipitation, as described previously (24). Samples were 
separated by 10% or 12.5% SDS-PAGE and transferred to Immobilon-P membranes 
(Millipore). Membranes were blocked in 3% milk/TBS/0.05% Tween 20 or 3% bovine serum 
albumin (BSA)/TBS/0.05% Tween 20 (for anti-phosphotyrosine, anti–phospho-STAT1, and 
anti–phospho-STAT3 blots). Immunoblotting was performed as previously described (26).  
 
Focus Assay 
Focus assays were performed using NIH3T3 cells plated at a density of 2 x 10
5
 
cells/60-mm plates in DMEM with 10% FBS 24 hr before transfection. Cells were transfected 
by Lipofectamine 2000 Reagent per manufacturer directions with 10 μg plasmid DNA. 
Between 22 and 24 hr after transfection cells were re-fed with DMEM 10% FBS. Cells were 
split 1:12 onto 100-mm plates between 22 and 24 hr later. Foci were scored at 12-14 days, 
fixed in methanol, stained with Geimsa stain, and photographed. Efficiency of transfection 
was determined by Geneticin (G418, 0.5 mg/ml)-resistant colonies plated at a dilution of 
1:240.  
 
Fractionation 
MCF7 cells were plated at a density of 1.5 x 10
6
 cells/100-mm plates 24 hr before 
transfection. Immediately prior to transfection, media was changed to DMEM 0% FBS with 
no antibiotic. Cells were transfected with 8 μg of plasmid DNA using Lipofectamine 2000 
Reagent, per manufacturer’s directions. 23 hr after transfection cells were collected in PBS 
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and 1 mM EDTA for fractionation as described previously (27). Separated fractions were 
analyzed for protein content by Bradford assay, separated by 10% SDS-PAGE, and 
transferred to Immobilon-P membrane for Western Blot analysis. 
 
IL-3 independent growth in 32D cells 
1x10
6
 exponentially growing 32D cells were electroporated (1500 V, 10 ms, 3 pulse) 
by the Neon Transfection System (Invitrogen) using 30 µg of FGFR3, FGFR3-TACC3 or 
PR/neu*  derivatives in pLXSN in triplicate. Twenty-four hours after transfection cells were 
selected with 1.5 mg/ml Geneticin (G418) sulfate for 10 days to generate stable cell lines. For 
IL-3 independent proliferation assays, 2x10
5
 cells were seeded in 12 well plates in the absence 
of IL-3 or 6 well plates in the presence of IL-3.  The media also contained 1 nM aFGF and 30 
μg/ml heparin (28). Cell numbers were determined in triplicate, with a hemocytometer and 
trypan blue exclusion on days 2, 4, 6 and 7. Media was added to cultures when cell numbers 
reached ~1x10
6 
cells/mL during the assays to maintain at viable concentrations. To measure 
cell viability MTT assays were performed. A stock solution of 5mg/ml in PBS of MTT 3-(4, 
5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (Sigma) was added at 1:10 to the 
cultures. After incubation at 37°C, 5% CO2 for approximately 4 hrs equal volume of 0.04 M 
HCl in isopropanol was added and mixed well and incubated again for at least 30 min (29). 
Cultures were transferred to microfuge tubes, spun for 30 sec at room temperature and 
supernatant absorbance was measured in a Beckman DU 350 UV/Vis spectrophotometer at 
570 nm. 5x10
4
 cells per well were plated in triplicate in 24-well plates in the presence or 
absence of IL-3 and 1nM aFGF and 30ug/ml heparin and assayed 3 days later. The cell 
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viability at day 7 was measured using the cultures from the proliferation assay. In triplicate, 
0.5 ml of the cultures were transferred to 24 well plates and treated with the MTT reagent.  
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CHAPTER 3 
 
Oncogenic Driver FGFR3-TACC3 is dependent on membrane trafficking and ERK 
signaling 
 
 
 
 
 
ABSTRACT 
Chromosomal translocations have been identified as oncogenic drivers in many 
cancers, allowing them to serve as potential drug targets in clinical practice. The involvement 
of FGFR genes in such translocations is becoming increasingly common, with FGFR3-
TACC3 fusion protein becoming frequently identified in many cancer types. We demonstrate 
that the oncogenic effect of FGFR3-TACC3 is dependent on entrance to the secretory 
pathway or plasma membrane localization, leading to overactivation of canonical 
MAPK/ERK pathway. FGFR3-TACC3 leads to cell transformation which can be enhanced by 
the introduction of different breakpoints of TACC3 but not by association with canonical 
TACC3 interacting proteins, Aurora-A, clathrin, and ch-TOG. We have shown that kinase 
inhibitors for MEK (Trametinib) and FGFR (BGJ398) are effective in blocking cell 
transformation and MAPK pathway upregulation. The development of personalized 
medicines will be essential in treating patients who harbor oncogenic drivers such as FGFR3-
TACC3. 
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3.1 INTRODUCTION 
Oncogenic driver mutations have taken a front seat in the world of cancer research. 
These drivers are often chromosomal rearrangements resulting in fusion proteins. A recently 
identified fusion protein is FGFR3-TACC3 (R3T3), which has been discovered in 
glioblastoma, lung cancer, bladder cancer, oral cancer, head and neck squamous cell 
carcinoma, gallbladder cancer, and cervical cancer (1,2). This fusion protein is formed by a 
tandem duplication on chromosome 4 resulting in a fusion of the fibroblast growth factor 
receptor 3 (FGFR3) gene with transforming acidic coiled-coil containing protein 3 (TACC3) 
gene.  
The FGFR family exhibits homologous domains of three immunoglobulin-like (Ig) 
domains, a transmembrane (TM) domain, and a split tyrosine kinase (TK) domain. FGFRs are 
activated by binding of fibroblast growth factor (FGF) ligands and heparin sulfate 
proteoglycans (HSPG) to the extracellular Ig-like domains. This induces FGFR dimerization 
and activation by trans-autophosphorylation of tyrosine residues in the kinase domain 
activation loop. FGFR activation leads to upregulation of RAS-MAPK, PI3K-AKT, and 
JAK/STAT pathways. This upregulation results in cellular proliferation, migration, 
angiogenesis and anti-apoptosis. In cancer, oncogenic fusion proteins involving FGFRs are 
becoming increasingly prevalent, with over 40 different FGFR fusion proteins detected so far 
(1). In such fusion proteins, the FGFR becomes constitutively activated by the dimerizing 
domain of the partner protein which brings the FGFR monomers close enough together to 
induce activation. In FGFR3-TACC3, the coiled-coil domain of TACC3 allows for 
autophosphorylation and activation of FGFR3 without the need for ligand binding (3).  
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 TACC3 belongs to the TACC family, which provides stability of the mitotic spindle. 
Aurora-A phosphorylation of TACC3 results in a complex formation of TACC3, clathrin and 
ch-TOG. This complex localizes to the mitotic spindle microtubules and assists in their 
stability and cross-linking of microtubules to kinetochores. Formation of this complex is 
essential for mitotic spindle stability and proper cell division (4,5). Alteration of TACC3 
expression levels has been found in many cancer types and leads to chromosomal segregation 
errors (6,7). These mitotic defects can contribute to aneuploidy and cancer progression (8).  
It has been demonstrated that the involvement of TACC3 in the fusion protein R3T3 
leads to an increased rate of aneuploidy and severe mitotic defects. Localization of R3T3 to 
the centrosome and mitotic spindle leads to chromosomal segregation errors and a reduction 
of TACC3 presence at the mitotic spindle (9,10). R3T3 has also been found to co-localize 
with phospho-PIN4 to induce preoxisome biogenesis and protein synthesis (11). Although 
altered cellular localization and effects on mitotic defects have been well explored, it is 
unclear if these effects are the drivers of cancer progression. It has also been demonstrated 
that the fusion protein R3T3 leads to an upregulation of PI3K/AKT, STAT and MAPK 
pathways (1,12). We demonstrate that the oncogenic mechanism initiated by R3T3 is through 
the overactivation of canonical FGFR pathways by entrance of R3T3 to the secretory pathway 
or localization to the plasma membrane. 
 
3.2 RESULTS 
Exploring the contribution of TACC3 in FGFR3-TACC3 
 TACC3 has been shown to localize to spindle microtubules and centrosomes during 
mitosis and to the cytoplasm and nucleus during interphase (13,14). The presence of the C-
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terminal coiled-coil domain of TACC3 in the R3T3 fusion protein has been shown to be 
responsible for the localization of R3T3 to the nucleus and to mitotic spindle poles (3,9). 
R3T3 has been reported to increase the rate of aneuploidy and chromosomal separation errors, 
due to the presence of R3T3 at the mitotic spindle and the absence of TACC3 WT at spindle 
microtubules (9,10). These data suggest that a nuclear-localized R3T3 could significantly 
accelerate cancer progression. To further examine the function of R3T3 localization, we 
employed a bipartite Nuclear Localization Signal (NLS) from Xenopus nucleoplasmin fused 
in frame with the kinase and coiled-coil domains of R3T3 in order to direct a nuclear-
localized population of R3T3 (NLS-R3T3) (15) (Figure 9A, 9D). Additionally, mutation of 
select positively charged residues to Gln in the NLS abrogates the nuclear localizing, resulting 
in a cytoplasmic-localized population of R3T3 (Figure 9A, 9D). Using these populations, 
which are designed to mimic TACC3 wild-type (WT) behavior during interphase (14), we 
investigated the effects of each R3T3 population on oncogenicity. Surprisingly, neither the 
nuclear- nor cytoplasmic-targeted populations of R3T3 resulted in cellular transformation, as 
shown by NIH3T3 focus assay (Figure 9B, 9C). This indicates that the previously identified 
nuclear localization of an overactivated FGFR3 receptor due to R3T3 fusion formation is not 
the driving force of NIH3T3 cell transformation. During interphase, the R3T3 fusion appears 
in vesicle-like structures, which is expected for a transmembrane protein and consistent with 
previous reports (10) (Figure 9D). However, the addition of the TACC3 domain does alter 
cellular localization, as FGFR3 wild-type (WT) displays both cytoplasmic and plasma 
membrane (PM) localization (Figure 9D). While the presence of R3T3 may contribute to 
mitotic chromosomal segregation errors and aneuploidy (9,10), this may not be the initial 
oncogenic driver of focus formation. 
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Figure 9: Nuclear-localized FGFR3-TACC3 does not convey cell transformation. (A) 
Schematic of FGFR3-TACC3 and NLS-FGFR3-TACC3 fusion proteins. For the nuclear-
localized fusion construct, the extracellular and TM domains of FGFR3 are replaced with a 
bipartite Nuclear Localization Sequence (NLS) (NLS-FGFR3-TACC3). Mutation of 
underlined residues to Q results in cytoplasmic-localized FGFR3-TACC3 (NLS*-FGFR3-
TACC3). (B) Transformation of NIH3T3 cells by FGFR3 and FGFR3-TACC3 derivatives. 
Number of foci were scored, normalized by transfection efficiency, and quantitated relative to 
FGFR3-TACC3 +/- SEM. (C) Representative plates from a focus assay are shown, with 
transfected constructs indicated. (D) Representative confocal micrographs of NIH3T3 cells 
stably expressing the indicated constructs. Secondary antibodies were either donkey anti-goat 
AlexFluor488 or donkey anti-goat AlexaFluor594. Nucleus is visualized with Hoechst 33342. 
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Figure 9. Nuclear-localized FGFR3-TACC3 does not convey cell transformation, continued. 
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Membrane localization is essential for FGFR3-TACC3 oncogenic activity 
 Following our results with the NLS signal, we replaced the extracellular and 
transmembrane domains of FGFR3 in R3T3 with a  myristoylation sequence derived from the 
N-terminus of c-Src (Myr-R3T3) (16,17) (Figure 10A). The addition of this sequence results 
in myristoylation of R3T3; myristoylation is a post-translational modification that adds 
myristic acid, a 14-carbon saturated fatty acid, to an N-terminal Gly residue, which directs 
R3T3 to the inner surface of the plasma membrane, in order to mimic an integral membrane 
protein (Figure 10B). This membrane association represents a non-covalent type of interaction 
with the membrane but is distinctly different from the membrane insertion of a classic type 1 
integral membrane protein such as FGFR3. FGFR3 requires an N-terminal signal sequence to 
direct entry into the secretory pathway, eventually reaching the cell surface after post-
translation modifications such as di-sulfide bonding and glycosylation. A mutant Gly2Ala 
myristoylation signal results in cytoplasmic localization of R3T3 (18) (Figure 10A,B). 
NIH3T3 cell focus assay demonstrates that only the plasma membrane-localized R3T3 leads 
to focus formation, while the cytoplasmic localized fusion protein was negative in this assay 
(Figure 10C,D). Additionally, transfection of Myr-R3T3 into HEK293T cells leads to 
significant upregulation of the MAPK pathway, suggesting a key mechanism of cell 
transformation (Figure 10E). This increase in MAPK phosphorylation is comparable to Myr-
FGFR3-K650E, which is a constitutively active myristoylated FGFR3 produced by the 
mutation K650E. This mutation was originally discovered as the cause of Thanatophoric 
Dysplasia type II, a skeletal disorder (1). Localization to the inner membrane face can 
produce a comparable level of cell pathway activation and transformation to R3T3, suggesting 
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that the driving oncogenic force of R3T3 is connected to the localization of a highly active 
FGFR3 kinase to the membrane in order to overactivate canonical RTK pathways.  
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Figure 10. Plasma membrane-localized FGFR3-TACC3 conveys cell transformation. (A) 
Schematic of FGFR3-TACC3 and Myr-FGFR3-TACC3 fusion proteins. For the membrane-
localized fusion construct, the extracellular and TM domains of FGFR3 are replaced with a 
myristoylation sequence (Myr) derived from c-Src (Myr-FGFR3-TACC3). Mutation of 
underlined residue to A results in cytoplasmic-localized FGFR3-TACC3 (Myr*-FGFR3-
TACC3). (B) Representative confocal micrographs of NIH3T3 cells stably expressing the 
indicated constructs, using FGFR3 immunostaining directed against an intracellular kinase 
domain peptide of FGFR3. Secondary antibodies were either donkey anti-goat AlexFluor488 
or donkey anti-goat AlexaFluor594. Nucleus is visualized with Hoechst 33342. (C) 
Transformation of NIH3T3 cells by FGFR3 and FGFR3-TACC3 derivatives. Number of foci 
were scored, normalized by transfection efficiency, and quantitated relative to FGFR3-
TACC3 +/- SEM. Assays were performed a minimum of three times per DNA construct. (D) 
Representative plates from a focus assay are shown, with transfected constructs indicated. (E) 
HEK293T cell lysates expressing FGFR3 or FGFR3-TACC3 derivatives were immunoblotted 
for phospho-MAPK (T202/Y204; top), MAPK (second panel), and FGFR3 (bottom). 
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Dual-targeted membrane associated fusion protein reinstates cell transformation 
 To assess if oncogenic activity can be restored to the biologically inactive nuclear-
localized R3T3, the myristoylation sequence was fused in frame 5’ of the NLS-FGFR3-
TACC3 gene, creating the fusion construct Myr-NLS-FGFR3-TACC3 (Figure 11A). Our goal 
was to determine if it is possible to override the function of the NLS using a myristoylation 
signal to reinstate plasma membrane association and cell transformation. Immunofluorescence 
analysis determined that in this dual-targeted construct, the myristoylation signal is able to 
supersede the NLS signal, localizing R3T3 to the plasma membrane (Figure 11B). 
Consequently, shifting the biologically inactive NLS construct to the membrane restores 
biological activity and cell transformation as indicated by focus assay (Figure 11C). Also 
restored is the overactivation of MAPK pathway signaling by expression of Myr-NLS-
FGFR3-TACC3 in HEK293T cells, furthering the connection between this pathway and cell 
transformation (Figure 11D). These results indicate the importance of FGFR3-TACC3 plasma 
membrane localization and MAPK pathway overactivation to cell transformation.  
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Figure 11. Re-localization to the plasma membrane reinstates NLS-FGFR3-TACC3 
oncogenic activity. (A) Schematic of FGFR3-TACC3, NLS-FGFR3-TACC3 and Myr-NLS-
FGFR3-TACC3 fusion proteins. NLS-FGFR3-TACC3 is the same fusion construct identified 
in Fig. 1A. For the Myr-NLS derivative, the c-Src Myr sequence is fused in front of the NLS-
FGFR3-TACC3 (Myr-NLS-FGFR3-TACC3). (B) Representative confocal micrographs of 
NIH3T3 cells stably expressing the indicated constructs, using FGFR3 immunostaining 
directed against intracellular kinase domain peptide of FGFR3. Secondary antibodies were 
donkey anti-goat AlexFluor488 or donkey anti-goat AlexaFluor594. Nucleus is visualized 
with Hoechst 33342. (C) Transformation of NIH3T3 cells by the indicated constructs. 
Number of foci were scored, normalized by transfection efficiency, and quantitated relative to 
FGFR3-TACC3 +/- SEM. Assays were performed a minimum of three times per DNA 
construct. (D) HEK293T cell lysates expressing FGFR3 or FGFR3-TACC3 derivatives were 
immunoblotted for phospho-MAPK (T202/Y204; top), MAPK (second panel) and FGFR3 
(bottom). 
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Cell transformation is dependent on entrance to the secretory pathway 
 The appearance of R3T3 in vesicle-like structures (Figure 9D) could indicate secretory 
vesicles en route to the membrane and that the fusion protein is capable of being inserted in 
the membrane as an integral membrane protein. To explore this, we blocked entrance of R3T3 
to the secretory pathway by deletion of the FGFR3 signal sequence contained in the first 22 
amino acids of the receptor (named ∆SS-FGFR3-TACC3) (19). The extracellular domain, 
transmembrane domain and kinase domain of FGFR3 and the coiled-coil domain of TACC3 
remain intact (Figure 12A). The N-terminal signal peptide is homologous in the FGFR family 
and is responsible for targeting the FGFR for secretion.  
We assessed co-localization of R3T3 and ∆SS-FGFR3-TACC3with a secretory 
pathway marker for early endosomes, EEA1, by confocal microscopy. Co-localization of 
R3T3 with this marker indicates its participation in membrane trafficking (Figure 12B, white 
arrows). Contrastingly, ∆SS-FGFR3-TACC3 does not co-localize with early endosomal 
EEA1 marker, confirming that entrance to the secretory pathway is blocked (Figure 12B). 
Analysis between R3T3 and markers for lysosomes (LAMP1), recycling endosomes (Rab11), 
or clathrin did not display co-localization (data not shown). As seen in Figure 12C, the 
multiple banding pattern of R3T3 (labeled with black arrow, lane 3) indicates different levels 
of glycosylation while ∆SS-FGFR3-TACC3 does not display this. Treatment of 
immunoprecipitated R3T3 with PNGase F to remove N-linked oligosaccharides results in a 
deglycosylated form of R3T3 with an electrophoretic mobility pattern identical to ∆SS-
FGFR3-TACC3 (Figure 12C, lanes 5 and 6). This confirms that ∆SS-FGFR3-TACC3 does 
not exist as a glycosylated protein and is therefore not undergoing post-translation 
modifications of the secretory pathway.  
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As determined by focus assay and immunoblot, blocking entrance to the secretory 
pathway also blocks focus formation, cell transformation, and MAPK pathway activation by 
R3T3. This demonstrates the need for R3T3 to enter the secretory pathway and undergo post-
translational processing, presumably reaching the plasma membrane in order to show 
oncogenic effects (Figure 12D, 12E). Some detectable MAPK pathway activation by ∆SS-
FGFR3-TACC3 indicates the FGFR kinase domain is able to activate this pathway in 
HEK293T cells, but not enough to initiate to cell transformation in NIH3T3 cells (Figure 
12E). Black arrows again demonstrate R3T3 has a multiple banding pattern indicating 
different levels of post-translational processing by the secretory pathway, where as ∆SS-
FGFR3-TACC3 does not display this (Figure 12E). 
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Figure 12. FGFR3-TACC3 presence in the secretory pathway produces oncogenic effects. (A) 
Schematic of FGFR3-TACC3 with detail of signal peptide. SS-FGFR3-TACC3 indicates 
FGFR3-TACC3 with signal peptide deleted. (B) Confocal analysis of NIH3T3 cells stably 
expressing the indicated constructs reveals that FGFR3-TACC3 (red) co-localizes (yellow) 
with EEA1 early endosome marker (green) suggesting involvement in the secretory pathway. 
(C) HEK293T cell lysates expressing indicated constructs were immunoprecipitated with 
FGFR3 antibody, divided, treated with PNGase F enzyme and immunoblotted with FGFR3 
antibody. (D) Transformation of NIH3T3 cells by the indicated constructs. Number of foci 
were scored, normalized by transfection efficiency and quantitated relative to FGFR3-TACC3 
+/- SEM. Assays were performed a minimum of three times per DNA construct. (E) 
HEK293T cell lysates expressing SS-FGFR3-TACC3 or FGFR3-TACC3 were 
immunoblotted for phospho-MAPK (T202/Y204; top), MAPK (second panel), and FGFR3 
(bottom). 
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Different TACC3 breakpoints produce altered and elevated cell transformation 
   FGFR3-TACC3 has been identified in human cancer with many different breakpoints 
between the two fused genes. Breakpoints have been found to occur within exon 16 to 19 of 
FGFR3 gene and within exon 4 to 11 of TACC3 (1). The most commonly identified R3T3 
fusion breakpoint is exon 18 of FGFR3 to exon 11 of TACC3, which this manuscript has 
focused on thus far. The second most common breakpoint of R3T3 is exon 18 of FGFR3 to 
exon 8 of TACC3. The introduction of the larger TACC3 gene introduces regulatory sites 
which are key to TACC3 wild-type (WT) function, including S558 Aurora-A phosphorylation 
site and LL566/567 clathrin binding domain, corresponding to S771 and LL779/780 in fusion 
protein R3T3 (Figure 13A). Upon Aurora-A phosphorylation, TACC3 WT will coordinate 
with ch-TOG (also named CKAP5) and clathrin to form a TACC3-ch-TOG-clathrin complex 
to assist with mitotic spindle binding (4,5). Immunofluorescence shows localization of 
R3T3ex8 to be very similar to R3T3ex11 during interphase (data not shown). However, by 
focus assay, R3T3ex8 displays 3-fold higher cell transformation level than R3T3ex11 (Figure 
13B). Interestingly, R3T3ex8 and R3T3ex11 display comparable levels of MAPK activation, 
indicating the increase in cell transformation is through an additional oncogenic mechanism 
(data not shown).  
To investigate factors contributing to the difference in focus formation between the 
two fusion breakpoints, abrogation of Aurora-A phosphorylation site or clathrin binding site 
by mutation to Ala was performed (Figure 13A). While abrogation of these two sites 
individually did lead to a significant decrease by Student’s T test (*p<0.05), mutation of both 
of these sites within the same fusion protein did not lead to a significant reduction in focus 
formation (Figure 13B). This would indicate that association with clathrin or phosphorylation 
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by Aurora-A via TACC3’s canonical pathway does not significantly contribute to cell 
transformation or the oncogenic mechanism of FGFR3-TACC3.  
TACC3 has been shown to interact with ch-TOG regardless of Aurora-A 
phosphorylation. This interaction allows the TACC3-ch-TOG complex to stabilize 
microtubule dynamics by binding to growing microtubule ends during interphase (20). The 
binding domain of ch-TOG has been mapped to a break in the coiled-coil domain of TACC3, 
residues 678 to 688 in TACC3 WT. The implications of the interaction between ch-TOG and 
R3T3 have not been investigated. Previous studies have shown that deletion of the first 4 
residues of this binding domain (RFEE) successfully disrupts the ch-TOG and TACC3 
interaction and prevents TACC3 from localizing to growing microtubule ends (4,20). Deletion 
of these 4 residues in R3T3ex11 (ex11-∆ch-TOG) yielded a 3-fold increase in focus formation 
relative to non-mutated R3T3ex11 (**p<0.01). Contrastingly, the same deletion in R3T3ex8 
(ex8-∆ch-TOG) did not yield a significant change in the amount of foci formed (Figure 13B). 
This could indicate that interaction of R3T3ex11 and ch-TOG inhibits the ability of R3T3 to 
convey cell transformation. 
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Figure13. TACC domain mutations and their contribution to cell transformation. (A) 
Schematic of FGFR3-TACC3ex11 and FGFR3-TACC3ex8 with ch-TOG binding domain 
indicated. Location of Aurora-A phosphorylation site (S771) and clathrin binding site 
(L779/L780) in FGFR3-TACC3ex8 are shown. (B) Transformation of NIH3T3 cells by the 
indicated constructs. Number of foci were scored, normalized by transfection efficiency, and 
quantitated relative to FGFR3-TACC3ex11 +/- SEM. Statistical analysis by Student’s t-test 
identifies significant changes in focus counts (*p<0.05, **p<0.01). Assays were performed a 
minimum of three times per DNA construct. 
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FGFR3 kinase activity and MAPK pathway upregulation are key to oncogenicity 
Our data indicates a distinct mechanism of action, in which cell transformation by 
R3T3 corresponds with MAPK pathway upregulation. A connection between these findings is 
further demonstrated by NIH3T3 cell focus assay, transfected with FGFR3-TACC3ex11, 
FGFR3-TACC3ex8 or FGFR3 K650E activating mutation and treated with increasing 
concentrations of either MEK1/2 inhibitor Trametinib (GSK1120212) or FGFR kinase 
inhibitor  BGJ398 (Figure 14B, 14C). Both inhibitors individually block focus formation 
leading to antitumor effects, demonstrating two potential therapeutic strategies. Interestingly, 
differences in sensitivity to BGJ398 can be seen between the two most common breakpoints 
of the fusion protein, R3T3ex11 and R3T3ex8 (Figure 14C). Complete inhibition of focus 
formation was achieved with 2.5nM of BGJ398 in cells transfected with R3T3ex11, while 
complete inhibition of R3T3ex8 required 5nM of BGJ398 indicating that distinctive fusion 
breakpoints respond to the inhibitor differently. Similar effects were seen for the two fusion 
breakpoints treated with Trametinib (Figure 14B). Combination of BGJ398 and Trametinib 
was effective in reducing cell transformation, but with less sensitivity than expected, 
suggesting that these inhibitors are not additive in this assay (Figure 14D). For FGFR3 
K650E, both inhibitors were successful in reducing focus formation, although with less 
sensitivity than seen with FGFR3-TACC3ex11 and FGFR3-TACC3ex8 (Figure 14B-D).  
To further demonstrate the importance of the MAPK pathway, R3T3ex11 was 
transfected into HEK293T cells and treated with increasing concentrations of either BGJ398 
or Trametinib. Both inhibitors effectively decrease phosphorylated MAPK, as determined by 
immunoblot (Figure 14A). Collectively, this data indicates a direct link between FGFR3 
activation by fusion to TACC3, upregulation of the MAPK pathway, and cell transformation.   
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Figure 14. Effect of MEK and FGFR inhibitors on cell transformation and MAPK pathway. 
(A) HEK293T cells expressing FGFR3-TACC3ex11 were treated with Trametinib or BGJ398 
at indicated concentrations and immunoblotted for phospho-MAPK (T202/Y204; top), MAPK 
(second panel), and FGFR3 (bottom). (B) Transformation of NIH3T3 cells expressing 
FGFR3-TACC3ex8, FGFR3-TACC3ex11 or FGFR3 K650E followed by treatment with 
indicated concentrations of MEK inhibitor (MEKi) Trametinib. (C) NIH3T3 cells expressing 
FGFR3-TACC3ex8, FGFR3-TACC3ex11 or FGFR3 K650E were treated with indicated 
concentrations of FGFR inhibitor (FGFRi) BGJ398. (D) NIH3T3 cells expressing indicated 
constructs were treated with a 1.25 nM Trametinib and varying concentrations of BGJ398. 
Number of foci were scored, normalized by transfection efficiency, and quantitated relative to 
FGFR3-TACC3ex8 +/- SEM. Assays were performed three times per DNA construct. 
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3.3 DISCUSSION 
We have clarified the cellular location of R3T3 required to initiate cell transformation 
and overactivation of the canonical MAPK pathway. We have demonstrated that R3T3 must 
enter the secretory pathway and reach the plasma membrane to lead to oncogenic cell growth 
(Figure 9-12). Post-translational processing and plasma membrane localization is also 
required for the overactivation of MAPK in HEK293T cells. MAPK overactivation in 
HEK293T cells is only seen for our R3T3 derivatives that induce cell transformation in 
NIH3T3 cells, indicating a link between this pathway and cell transformation (Figure 10, 11). 
The essentiality of the MAPK pathway activation to cell transformation is demonstrated by 
the use of Trametinib, a MEK inhibitor, which blocks cell transformation by R3T3 in NIH3T3 
cells. FGFR inhibitor BGJ398 is also able to block focus formation indicating kinase activity 
is required for cell transformation. Both inhibitors display unique levels of inhibition against 
different R3T3 fusion protein breakpoints, specifically R3T3ex11 and R3T3ex8, 
demonstrating the need for personalized treatment of cancers depending on the fusion 
breakpoint (Figure 14). Additionally, R3T3 contains TACC3 functional sites, the Aurora-A 
phosphorylation site, clathrin binding site and ch-TOG binding site. However, interaction 
with these proteins does not significantly contribute to the ability of R3T3 to induce cell 
transformation (Figure 13).  
The appearance of R3T3 in vesicle-like structures by IF in NIH3T3 cells is an 
indicator of secretory vesicles en route to the membrane and that the fusion protein is capable 
of being inserted in the membrane as a type 1 integral membrane protein (Figure 9, 12). Upon 
reaching the membrane, internalization of the fusion protein could occur quickly due to its 
high level of activation without the need for ligand binding. Additionally, nuclear and 
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cytoplasmic localization of R3T3 does not contribute to cell transformation (Figure 9, 10). 
Our results indicate that in order to induce cell transformation in NIH3T3 cells, R3T3 must 
undergo post-translational processing via the secretory pathway, presumably reaching the 
membrane in order for cell transformation and MAPK pathway overactivation to occur. 
Prevention of entrance to the secretory pathway also blocks post-translational modifications, 
cell transformation and reduces MAPK overactivation (Figure 12). Myristoylation of R3T3 
indicates the importance of plasma membrane association for inducing cell transformation and 
overactivation of canonical FGFR3 pathways. Previous studies by our lab and others have 
identified R3T3-induced overactivation of MAPK and PI3K/AKT pathways, which drives of 
cell proliferation leading to acceleration of the cell cycle and cancer progression (3,21). This 
indicates that R3T3 increases oncogenic growth by overactivation of cell growth pathways, 
not by an altered localization of R3T3 by the TACC3 domain to the nucleus, centrosome, or 
mitotic spindle, as previous studies have suggested (3,9,10). 
Our work with R3T3ex8 demonstrates the fusion protein’s oncogenic effects are not 
due to mitotic involvement via TACC3’s canonical pathway. Abrogation of Aurora-A 
phosphorylation, clathrin and ch-TOG binding sites in R3T3ex8 displayed no significant 
change in focus formation demonstrating that interaction with these proteins does not effect 
the biological activity of R3T3ex8. In R3T3ex11, deletion of ch-TOG binding site increases 
focus formation, further demonstrating that interaction with ch-TOG does not contribute to 
oncogenic activity (Figure 13). Interaction between R3T3 and ch-TOG may in fact have an 
inhibitory role in cell growth. Previous studies have found that it is a removal of TACC3 from 
the mitotic spindle or a presence of R3T3 at the centrosomes that leads to chromosomal 
segregation errors during mitosis (9,10). However, incorrect cell division due to R3T3 does 
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not appear to be the key oncogenic driver in cells expressing this fusion. Consistently, studies 
analyzing the recruitment of other tyrosine kinases to the centrosome by fusion protein 
formation found centrosomal targeting to be unessential to oncogenic progression (22). We 
have demonstrated that involvement with TACC3 canonical interacting proteins is not the 
driving force of oncogenicity.  
 Interestingly, we demonstrate a difference in oncogenic activity between two 
breakpoints of R3T3 (R3T3ex8, R3T3ex11) and how those breakpoints respond differently to 
the same inhibitor treatment. The use of kinase inhibitors stresses the importance of 
personalized treatment not only for knowing if a specific RTK inhibitor is useful, but also 
how that inhibitor affects various fusion breakpoints or cancer genotypes. We demonstrated 
inhibition of MEK and FGFR as two potential therapeutic strategies for cancers that harbor 
the R3T3 rearrangement. This data is also supported by inhibition of MEK and FGFR in 
cervical cancer cell lines to reduce cell proliferation (23). Assessment of several FGFR 
inhibitors against R3T3 or other FGFR alterations in clinical trials is currently underway 
[clinicaltrials.gov]. A clinical trial enrolling patients with similar genomic alterations but 
various cancer types may prove useful in determining the efficacy of an inhibitor against 
different genomic backgrounds (23). The fact that inhibitors display different levels of 
effectiveness against varied genomic backgrounds is supported not only by our work but also 
by those exploring inhibition of R3T3 in concert with PI3K inhibition (24). This demonstrates 
a need for personalized cancer treatment and precision medicine.  
 This manuscript characterizes the need for R3T3 to be in the secretory pathway or at 
the cell membrane to induce cell transformation. The activation of the MAPK pathway is 
essential for cell transformation but involvement in the cell cycle via TACC3’s canonical 
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pathways is not. We have shown that kinase inhibitors for MEK and FGFR are effective in 
blocking cell transformation and MAPK pathway upregulation. The need for precision 
medicine is evidenced by the different inhibitory effects these inhibitors have against various 
R3T3 breakpoints. The development of such personalized medicines will be essential in 
treating patients who harbor oncogenic drivers such as FGFR3-TACC3.  
 
3.4 MATERIALS AND METHODS 
DNA constructs 
FGFR3-TACC3 gene was constructed as previously described (3). For derivation of 
plasma membrane- and nuclear-localizing constructs, myristoylation signal from c-Src or 
nuclear localization signal from Xenopus nucleoplasmin was utilized as previously described 
(18). Briefly, each sequence was ligated in place of the extracellular and transmembrane 
domains of FGFR3 resulting in fusion to residues 400 to 806 of FGFR3 or residues 400 to 
953 in FGFR3-TACC3. For deletion of signal sequence of FGFR3, residue 2 to 22 were 
deleted following the site-directed mutagenesis protocol of Liu and Naismith. Deletion of ch-
TOG domain followed the same protocol and deleted TACC3 residues RFEE, 792-795 in 
FGFR3-TACC3 or 678-681 in TACC3 (25). Aurora-A and clathrin mutations were achieved 
by Quikchange site-directed mutagenesis.  
 
Cell culture 
HEK293T cells were cultured in 10% FBS DMEM plus 1% penicillin/streptomycin in 
10% CO2 at 37°C. NIH3T3 cells were maintained in 10% CS DMEM and 1% 
penicillin/streptomycin in 10% CO2 at 37°C. 
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Antibodies and reagents 
Antibodies were purchased from: FGFR3 (B-9), FGFR3 (P18) from Santa Cruz 
Biotechnology; FGFR3 (OAAB11172) from Aviva Systems Biology; phospho-p44/42 MAPK 
(ERK 1/2; T202/Y204; D13.14.4E), p44/42 MAPK (ERK 1/2, 9102) from Cell Signaling 
Technology; EEA1 (610456) from BD Biosciences; Alexa Fluor 488 donkey anti-goat 
(A11055), Alexa Fluor 594 donkey anti-goat (A11058), Alexa Fluor 488 donkey anti-mouse 
(A21202) from Invitrogen; horseradish peroxidase (HRP) anti-mouse, HRP anti-rabbit, and 
Enhanced Chemiluminence (ECL) reagents were from GE Healthcare. Geneticin (G418) was 
from Gibco, and Lipofectamine 2000 was from Invitrogen. PNGase F was purchased from 
NEB (P0704S) and Pierce Protein A/G Magnetic Beads (88802) were purchased from 
Thermo Fisher. Inhibitors BGJ398 (S2183) and Trametinib (S2673) were purchased from 
Selleckchem.  
 
Immunoprecipitation and immunoblot analysis 
24 h before transfection, HEK293T cells were plated at 1x10
6
 cells/100-mm plate. 
Calcium phosphate method was used to transfect 3 μg plasmid DNA in 3% CO2 as described 
previously (3). For immunoblot analysis, after cell starvation and collection, cells were lysed 
in RIPA buffer [50 mmol/l Tris-HCl (pH 8.0), 150 mmol/l NaCl, 1% TritionX-100, 0.5% 
sodium deoxycholate, 0.1% SDS, 50 mmol/l NaF, 1 mmol/l sodium orthovanadate, 1 mmol/l 
PMSF, and 10 mg/ml aprotinin]. Total protein concentration was measured using Lowry 
assay. For immunoprecipitation, cells were lysed in 1% NP40 Lysis Buffer [20 mmol/l Tris-
HCl (pH 7.5), 137 mmol/l NaCl, 1% Nonidet P-40, 5 mmol/l EDTA, 50 mmol/l NaF, 1 
mmol/l sodium orthovanadate, 1 mmol/l phenylmethylsulfonylfluoride (PMSF), and 10 
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mg/ml aprotinin]. Protein concentration was measured by Bradford assay. Lysates were 
incubated overnight with antibodies at 4°C with rocking. Complexes were collected with 
Pierce Protein A/G Magnetic Beads (88802) according to manufacturers protocol. For 
PNGase digest, PNGase F Protocol from manufacturer NEB was followed.  
10% or 12.5% SDS-PAGE  separated samples before transfer to Immobilon-P PVDF 
membranes (Millipore). Membranes were blocked in 3% bovine serum albumin 
(BSA)/TBS/0.05% Tween 20 or 3% milk/TBS/0.05% Tween 20. Immunoblotting was 
completed as previously described (26). 
 
Immunofluorescence 
Stable cell lines were created by transfecting NIH3T3 cells with Lipfectamine 2000 
with FGFR3-TACC3 derivatives in pLXSN vector with Geneticin as the selectable marker. 
Cells were grown in 500 μg/ml G418 supplemented media for 14 days. Cell lines were 
created for all constructs except FGFR3 WT and ∆SS-FGFR3-TACC3. Stable cell lines were 
plated on 60mm plates with 6 coverslips at 1 x 10
5
 cells per plate. Coverslips were PLL 
coated (Neuvitro, GG-12-1.5-PLL). 24 h after plating, cells were starved with 0% serum 
DMEM for additional 24 h. Coverslips were fixed with 4% paraformaldehyde/PBS for 10 
min. 
For FGFR3 WT and ∆SS-FGFR3-TACC3, NIH3T3 cells were plated at 2 x 105. 24 h 
after plating, cells were transfect with Lipofectamine 2000. 18-20 h after transfection, cells 
were refed with 10% CS DMEM for 6 h until media was changed to 0% serum DMEM for 24 
h. Cells were fixed with 4% paraformaldehyde/PBS for 10 min.  
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For immunofluorescence staining, cells were permeabilized with 0.1% Triton X-
100/PBS for 20 min, blocked with 5% BSA/PBS before incubation with primary antibodies, 
goat anti-FGFR3 (1:500 or 1:1500) or EEA1 (1:25). After washes, cells were treated with 
secondary antibodies, donkey anti-goat Alexafluor488 (1:2000), donkey anti-goat 
Alexafluor594 (1:1500), or donkey anti-mouse Alexafluor 488 (1:250). Nucleus is visualized 
with Hoechst 33342 (1μg/ml, 15 min). Cells were examined on Leica SP5 
Confocal/MultiPhoton microscope (UC San Diego Neuroscience Core Facility). Images were 
processed with Leica LAS Lite and FIJI software. 
 
Focus assay 
NIH3T3 cells were plated at a density of 4x10
5
 cells/60-mm plates in 10% CS DMEM 
24 h before transfection. Lipofectamine 2000 Reagent was used to transfect cells with 10 μg 
plasmid DNA. Cells were re-fed with DMEM 10% CS 22-24 h after transfection. Cells were 
split 1:12 onto duplicate 100-mm plates 24 h later with 2.5% CS DMEM. Cells were refed 
every 3-4 days. After 14 days, foci were scored, fixed with methanol, and Geimsa stained. 
Transfection efficiency was determined by Geneticin (G418, 0.5 mg/ml)-resistant colonies 
plated at 1:240 dilution. Number of foci were scored, normalized by transfection efficiency, 
and quantitated relative to FGFR3-TACC3 +/- SEM. Assays were performed a minimum of 
three times per DNA construct. Statistical analysis by Student’s t-test identifies significant 
changes in focus counts and a two-tailed P-value of 0.05 was considered significant. 
For inhibitor treatment, 24 h after splitting cells 1:12 onto 100-mm plates, cells were 
refed with 2.5% CS DMEM containing indicated concentrations of BGJ398 or Trametinib. 
Cells were refed with 2.5% CS DMEM with the same inhibitor concentrations every 3-4 days. 
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After 14 days, foci were scored, fixed with methanol, and Geimsa stained. Transfection 
efficiency was determined by Geneticin (G418, 0.5 mg/ml)-resistant colonies plated at 1:240 
dilution. 
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CHAPTER 4 
 
Receptor Tyrosine Kinases: Translocation Partners in Hematopoietic Disorders 
 
 
 
 
ABSTRACT 
Receptor tyrosine kinases (RTKs) activate various signaling pathways and regulate 
cellular proliferation, survival, migration and angiogenesis. Malignant neoplasms often 
circumvent or subjugate these pathways by promoting RTK over-activation through mutation 
or chromosomal translocation. RTK translocations create a fusion protein containing a 
dimerizing partner fused to an RTK kinase domain, resulting in constitutive kinase domain 
activation, altered RTK cellular localization, upregulation of downstream signaling and novel 
pathway activation. While RTK translocations in hematological malignancies are relatively 
rare, clinical evidence suggests patients with these genetic abnormalities benefit from RTK-
targeted inhibitors. This chapter presents a timely review of an exciting field by examining 
RTK chromosomal translocations in hematological cancers, particularly ALK, FGFR, 
PDGFR, RET, CSF1R and NTRK3 fusions, and current therapeutic options. 
 
4.1 RECEPTOR TYROSINE KINASE TRANSLOCATIONS IN CANCER 
Malignant genetic events can often be sorted in two categories: gene inactivation and 
gene activation or deregulation. Chromosomal translocations have been detected in all cancer 
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types and account for approximately 20% of all malignant neoplasms (1). Moreover, there is a 
close correlation between the translocations and the tumor phenotypes in which they occur 
(1). 
Translocations usually arise by multiple erroneous double stranded breaks (DSB) in 
chromosomes which may occur for various reasons. The translocation also relies on spatial 
proximity of the DSB and the ability of the damaged region to rearrange in the nucleus, which 
can allow the chromosomes to incorrectly repair (2, 3). These translocations can result in a 
translatable fusion protein, some of which have oncogenic potential. While the percentage of 
chromosomal translocations in hematological disorders is generally lower than solid tumors 
(1.4% of all hematological cancers) their occurrence is nevertheless significant, especially in 
diseases such as chronic myeloid leukemia (CML), where 100% of cases harbor the 
t(9;22)(q34;q11) translocation, resulting in the gene fusion of breakpoint cluster region (BCR) 
and ABL1, a non-receptor tyrosine kinase (1). CML is a classic example of a translocation-
driven disease that is amenable to treatment with a tyrosine kinase inhibitor (TKI). Imatinib, 
also known as Gleevec, has been widely used to treat CML and diseases presented by some of 
the fusion proteins discussed in this review. CML treatment with imatinib has ushered in a 
new era of rational drug development to identify TKIs with therapeutic value. 
This chapter will focus on translocations involving receptor tyrosine kinases (RTKs) 
in hematological cancers (Figure 15). Of the 58 known human RTKs, the following have been 
identified as fusion partners resulting from chromosomal translocations in hematopoietic 
cancer cells: Anaplastic Lymphoma Kinase (ALK), Fibroblast Growth Factor Receptor 
(FGFR), Platelet-Derived Growth Factor Receptor (PDGFR), REarranged during Transfection 
(RET), Colony Stimulating Factor 1 Receptor (CSF1R) and Neurotrophic Tyrosine Kinase 
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Receptor Type 3 (NTRK3). As reviewed in this chapter, the most common hematopoietic 
cancer RTK translocations include the genes that encode ALK, FGFR and PDGFR. As 
discussed, these translocations results in cancers that present with different proliferative 
effects and treatment options, which highlights the importance of determining cancer-causing 
genetic alterations in patients. 
 
 
Figure 15. General Structural Schematic of RTK Fusion Proteins. Depicted are ALK, FGFR, 
and PDGFR fusion proteins, showing a generic dimerization domain for each. A star indicates 
an alternate breakpoint; a triangle indicates kinase insert domain; TM is transmembrane 
domain; WW is WW-like domain; P is phosphorylation site. Each of these RTK fusion 
proteins displays a dimerization domain fused to a C-terminal kinase domain provided by the 
respective RTK. The dimerization domains commonly associated with each RTK fusion 
protein are shown in the outlined box. 
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4.2 ALK TRANSLOCATIONS: FUSION PROTEINS INVOLVING THE ONLY RTK 
NAMED FOR A DISEASE 
ALK regulation normally occurs by ligand binding to its extracellular domain. ALK 
expression occurs in the central and peripheral nervous system, primarily during development, 
as shown in multiple species, including human (4). After birth, as shown in mouse studies, 
ALK mRNA and protein levels reach a minimum in all tissues and remain at low levels in 
adult animals (4). As such, Alk-knockout (KO) mice display only mild behavioral phenotypes 
and ALK inhibitors appear to be well tolerated in patients presenting with ALK-positive 
lymphoma (4). ALK was initially identified in a human t(2;5)(p23;q35) translocation, fusing 
Nucleophosmin (NPM1) to ALK, expressing the fusion protein NPM-ALK leading to 
overexpression and constitutive activation of NPM-ALK kinase activity (5). This fusion 
protein occurs in 50-60% of anaplastic large cell lymphomas (ALCL) (6). The two main 
forms of ALCL are primary cutaneous, which affects the skin, and systemic, which can be 
divided into ALK-positive and ALK-negative subgroups. ALK fusion-positive ALCL tends to 
occur in younger patients and has a greater disease-free and overall survival rates than 
patients with ALK fusion-negative ALCL (7). 
ALK fusion proteins are a recurring abnormality in ALCL, accounting for 2% of adult 
non-Hodgkin’s lymphomas (NHL) and 13% of pediatric NHL (8). Some of the N-terminal 
ALK fusion partners in ALCL include clathrin heavy chain gene (CLTC), nucleophosmin 
(NPM), tropomyosin 3 (TPM3), TPM4, and TNF receptor-associated factor 1 (TRAF1) (4, 5, 
7, 9). A complete list is shown in Table 2. All ALK fusion partners contain dimerization 
domains in the N-terminal fusion partner fused to the C-terminal ALK kinase domain (4) 
(Figure 15). While NPM-ALK is the most common translocation, 15-28% of ALK fusion-
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positive cases display an alternative ALK fusion protein (5). ALK fusion proteins have also 
been detected in diffuse large B cell lymphoma (DLBCL), a rare but aggressive B cell 
lymphoma. The most common ALK translocation partner in this disease is CLTC (4). In 
addition, the translocation partner must exhibit active promoter activity, as ALK is not 
typically expressed outside of the nervous system or after birth (4, 6). The initiation of 
transcription of the fusion protein thus relies on the promoter sequence of the 5’ fusion gene. 
The most common hematological ALK fusion, NPM-ALK, arises from the 
translocation t(2;5)(p23;q35) between ALK on human chromosome 2 and NPM1 on 
chromosome 5. The ALK tyrosine kinase domain becomes constitutively activated by 
formation of homodimers mediated by the self-associating domain of nucleophosmin (NPM). 
This dimerization is essential for oncogenic transformation by NPM-ALK, which is capable 
of transformation of various cell types, IL-3 independent proliferation of Ba/F3 lymphocytes 
by interaction with PLCγ, and activation of PI3K, AKT and STAT5. Additionally, a human 
lymphoblastic Jurkat T cell line stably expressing NPM-ALK displays PI3K and PLCγ-
independent inhibition of doxorubicin-induced apoptosis (5). 
Although the NPM1 domain is essential to oncogenic activity, this domain is also 
responsible for nuclear localization of the fusion protein, as its normal role is an RNA-binding 
nucleolar phosphoprotein. NPM-ALK is the only ALK fusion protein identified so far that 
displays nuclear localization (5, 10) (Figure 16). While NPM-ALK is detected in the 
cytoplasm and the nucleus, only the cytoplasmic fusion protein exhibits an active ALK kinase 
domain (10). The nuclear population is inactivated by dimerization with WT NPM1, which 
includes nuclear (NLS) and nucleolar localization signals (NuLS) not included in the NPM-
ALK fusion protein. Formation of NPM-ALK/NPM1 heterodimers does not allow the ALK 
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kinase to become activated by trans-phosphorylation but does result in nuclear localization. 
Cytoplasmic expression appears to be a requirement for cell transformation, as this is the 
location of many other ALK fusion proteins (11) (Figure 16). Altered localization of a 
strongly activated tyrosine kinase may result in interaction with and phosphorylation of novel 
proteins and pathways. 
 
 
Figure 16. Cellular localization of various RTK fusion proteins. The identified localization of 
the parent RTKs and the resulting fusion proteins are shown. The RTK fusion proteins are 
depicted in their corresponding localization site. These RTK fusions may localize in the 
plasma membrane, centrosome, nuclear membrane, nucleus or cytoplasm.  
 
Studies have emerged identifying spatial organization of the genome as a cause for 
recurring translocations in lymphomas (12). Specifically, in ALCL there are several 
dysregulated genes surrounding the chromosomal breakpoints for ALK and NPM1. In ALK 
fusion-negative cells, the breakpoint regions of the t(2;5) translocation are in close proximity 
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within the nucleus but not yet fused. This allows for the experimental generation of this 
translocation. The spatial proximity of NPM and ALK genes does not exist in non-ALCL 
cells, such as Jurkat and KE-37 (T-cell leukemia) cell lines (13). The t(2;5) translocation may 
not be the initial transformation event for the development of ALCL, a hypothesis supported 
by the fact that not all ALCL cases display this NPM-ALK fusion protein (13). Nevertheless, 
the presence of ALK fusion proteins in cancer cells leads to increased proliferation and cancer 
viability presenting a potential therapeutic target. 
 
4.3 FGFR TRANSLOCATIONS: RELATIVELY RARE BUT PROVIDING 
IMPORTANT INSIGHTS 
FGFRs are often aberrantly activated in cancer by overexpression, mutation, or 
translocation (14). In early hematopoietic cells, FGFRs are usually poorly expressed but as 
cells mature, FGFR expression generally increases. Human leukemia cells have been shown 
to express at least one type of receptor (FGFR1, FGFR3, or FGFR4) (15, 16). 
FGFR1 is involved in 8p11 myeloproliferative syndrome (EMS), also known as stem 
cell leukemia-lymphoma syndrome (SCLL). EMS involves a chromosomal translocation that 
produces a dimerizing protein partner fused N-terminally to the kinase domain of FGFR1, 
normally encoded at the 8p11 locus. EMS is a rare, aggressive myeloproliferative disorder 
that can quickly progress into acute myeloid leukemia (AML) (17). 
FGFR1 fusion partners in EMS are many and varied (Table 2), some of which include 
breakpoint cluster region (BCR), cut-like homeobox 1 (CUX1), FGFR1 oncogenic partner 
(FGFR1OP) and zinc finger 198 (ZNF198) (14). Interestingly, many of these partners also 
contain leucine zipper, leucine rich and coiled-coil domains. The contribution of a 
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dimerization domain by each fusion partner is necessary for the phosphorylation and 
activation of the FGFR1 kinase domain, resulting in a gain-of-function fusion protein. 
Additionally, given that biologically active translocations result from the in-frame fusion of 
two coding sequences that are normally distinct, this dictates that expression of the FGFR1 
kinase domain in these fusions is reliant on the promoter sequence of the partner N-terminal 
protein. 
In patients with EMS, the presence of an 8p11 translocation does not always mean an 
FGFR1 rearrangement. Studies have identified a small subset of 8p11 translocations as 
rearrangements of the histone lysine acetyltransferase KAT6A (KAT6A gene), also located at 
the same chromosomal region as FGFR1. KAT6A has several translocation partners occurring 
in 2% of AML cases (18). FISH analysis is recommended for patients with EMS and 8p11 
rearrangements in order to identify the correct translocation, allowing treatment with TKI 
therapeutics, such as ponatinib and dovitinib, for those expressing FGFR1 fusion proteins (19-
21). 
Though not as common, FGFR3 is also involved in translocations in hematopoietic 
disorders. Ets variant 6 (ETV6, previously known as TEL, translocation-ets-leukemia) is 
fused to FGFR3, and is found in T-cell lymphomas which progress to AML. Wild type (WT) 
ETV6 contains a helix-loop-helix (HLH) domain and serves as a transcription factor. The 
fusion of ETV6 to FGFR3 arises from the t(4; 12)(p16;p13) translocation and leads to the 
HLH domain of ETV6 fused to the transmembrane domain of FGFR3. The HLH domain is a 
dimerization domain, allowing constitutive activation of the FGFR3 kinase domain. The 
ETV6-FGFR3 fusion leads to IL-3 independent growth in Ba/F3 cells, activation of STAT3, 
STAT5, MAPK and PI3K, and exhibits cytoplasmic localization (22). 
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Multiple myeloma (MM) commonly contains a t(4;14) translocation between IgH 
promoter to the MMSET and FGFR3 genes, a translocation which does not result in a novel 
FGFR3 fusion protein but rather overexpression. MMSET overexpression is observed in all 
translocation-positive cases and FGFR3 overexpression in 70% of translocation-positive 
cases, which often exhibit activating point mutations in FGFR3 as well (14, 23). This 
overexpression leads to IL-6 independent growth in murine B9 cells, upregulated MAPK and 
PI3K signaling, and induced lymphoid malignancies in mice (15, 23). In chronic lymphocytic 
leukemia (CLL), rare translocations between FGFR3 and IgH (t(4;14)(p16;q32)) and IgL 
(t(4;22)(p16;q11.2) have been identified (14, 24). These types of translocations resulting in 
altered FGFR3 expression are medically important, yet they are distinct from the other 
translocations reviewed here which fuse two distinct reading frames to create a novel fusion 
protein.  
The most commonly identified FGFR1 fusion protein is ZNF198-FGFR1, found in 
48% of EMS cases (17). Endogenous ZNF198, also known as ZMYM2, contains a zinc finger 
related motif, a proline rich domain and a MYM domain, and is suggested to serve as a 
transcription factor (17, 25). The fusion of ZNF198 and FGFR1 arises from the 
t(8;13)(p11;q12) human translocation, in which ZMYM2, the gene encoding ZNF198 on 
chromosome 13, is fused 5' to FGFR1 on chromosome 8. This fusion occurs in both myeloid 
and lymphoid cells, suggesting a multipotent hematopoietic progenitor cell origin. The N-
terminal ZNF198 domain, particularly the proline rich domain, facilitates dimerization and 
activation of the FGFR1 kinase domain (17). The ZNF198-FGFR1 fusion is oncogenic, as 
shown by IL-3 independent Ba/F3 cell proliferation, increased tyrosine phosphorylation of 
STAT1 and STAT5, as well as activation of PLC-γ, PI3K/AKT and notch signaling pathways 
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(26-28). While WT ZNF198 displays nucleolar localization, the fusion protein exhibits 
cytoplasmic localization (25) (Figure 16). 
BCR-FGFR1 is another commonly identified fusion protein in EMS. BCR contains a 
coiled-coil domain, possesses serine/threonine kinase activity and is a GTPase activating 
protein for Rac1 (29). BCR is more commonly found fused to ABL to form the BCR-ABL 
oncogene, where ABL encodes a non-receptor tyrosine kinase. This BCR-ABL fusion results 
from the Philadelphia chromosome, where exon 1 of BCR is fused to exon 2 of ABL, found in 
95% of CML patients (30, 31). Cases positive for other fusion proteins, including BCR-
FGFR1 fusion, are considered atypical CML (aCML). Both CML and aCML share similar 
phenotypes, as both are myeloproliferative disorders of hematopoietic stem cells, 
characterized by leukocytosis and a high number of immature granulocytes (30). 
The fusion of BCR and FGFR1, resulting from a t(8;22) (p11;q11) translocation, 
occurs commonly in EMS but is also observed in AML and B-cell lymphomas. The BCR-
FGFR1 fusion differs from the BCR-ABL fusion, as BCR exon 4 is fused to FGFR exon 9 
(32). This fusion gives rise to a kinase-kinase fusion product, with the serine-threonine kinase 
domain of BCR fused to the tyrosine kinase domain of FGFR1. The kinase domain of FGFR1 
becomes constitutively activated as a result of this fusion, leading to activation of STAT3, 
STAT5 and MAPK3/1 pathways and IL-3-independent proliferation of Ba/F3 cells (33). The 
BCR-FGFR1 fusion protein localizes to the cytoplasm, but it is unknown what role this plays 
in its oncogenicity (34) (Figure 16). The discovery and further characterization of FGFR 
fusion proteins arising from translocations is vital to determine the extent of signaling and 
proliferation that occurs due to different fusion partners. 
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4.4 PDGFR TRANSLOCATIONS: FUSION PROTEINS AND THEIR CANCERS 
Similar to other hematopoietic translocations, PDGFR fusion proteins express the 
RTK kinase domain as the C-terminal fusion protein partner whose expression is now reliant 
on the promoter of the gene encoding the N-terminal fusion protein. Unlike ALK receptors, 
WT PDGFRs are expressed at constant low levels in hematopoietic human and mouse cells 
(35). However, as shown using murine hematopoietic chimeras reconstituted with pdgfrb(-/-) 
fetal liver cells, PDGFR expression is not required for normal hematopoiesis (36). 
Although translocations creating PDGFR fusion proteins is low, a number of different 
fusion protein partners have been reported. Translocations have been reported that result in 
PDGFRA fused to BCR, FIP1-like 1 (FIP1L1) and striatin (STRN). For fusions with 
PDGFRB, many fusion partners have been reported including myosin 18A (MYO18A), 
Rab5A, tropomyosin 3 (TPM3) and others (Table 2). Both PDGFRA and PDGFRB have been 
found fused to ETV6. In myelodysplastic/myeloproliferative neoplasms (MDS/MPNs), 1.8% 
of cases appear to contain translocations encoding PDGFRB fusions proteins (37). As with 
ALK and FGFR translocations, most of these fusion partners contain dimerization domains 
which are essential for constitutive activation of the PDGFR receptor -- an exception being 
FIP1L1-PDGFRα. 
For WT PDGFR, dimerization alone is not enough to constitute receptor activation. 
Activation of the kinase domain also relies on reorganization and homotypic interaction of the 
extracellular Ig-like domain D4 between PDGFR receptors (38). However, in PDGFR fusion 
proteins, the extracellular domains are no longer present, yet the kinase domain is 
constitutively active (Figure 15). This indicates that an altered mechanism of activation which 
relies on the fused N-terminal dimerization domain is taking place. 
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One potentially interesting rearrangement results in the kinase domain of BCR fused 
to the kinase domain of PDGFRα, similar to the BCR-FGFR1 and BCR-ABL fusion proteins. 
This t(17;13) translocation between BCR and PDGFRA was reported in atypical CML 
(aCML), CEL, B/myeloid mixed phenotype leukemia and T acute lymphoblastic leukemia (T-
ALL). Only a few cases of BCR-PDGFRα have been reported with varying breakpoints: exon 
7, 12, or 17 for BCR fused to exon 12 or 13 of PDGFR (39, 40). In order to determine the 
extent of activation, signaling and proliferative differences contributed by the different fusion 
partners, a molecular analysis of BCR-PDGFRα with BCR-FGFR1 or BCR-ABL, comparing 
their relative extents of oncogenicity or clinical disease, may prove interesting. 
The most common PDGFRB fusion partner is ETV6, defined by t(5;12)(q33;p13) and 
identified in chronic myelomonocytic leukemia (CMML). ETV6 has also been found fused to 
PDGFRA in one patient (41). The ETV6 domain contains a HLH dimerization domain which 
allows for ligand-independent activation of the PDGFR receptor. Increased cell proliferation 
and transformation demonstrated by ETV6-PDGFRβ is reliant on increased fusion protein 
stability by reduced ubiquitination and increased STAT5 activation in Ba/F3 cells and mouse 
models (42). Murine stem cell differentiation is induced by the ETV6-PDGFRβ fusion protein 
through MAPK and STAT5 pathway activation (43). 
The ETV6-PDGFRβ fusion protein, along with FIP1L1-PDGFRα and ZNF198-
FGFR1, displays increased stability by evading ubiquinitation and degradation (44). To 
prevent overactivation, RTKs are often controlled by proteosomal degradation, negative 
feedback signals and, upon ligand binding, the complex is internalized and degraded. 
Additionally, the PDGFR juxtamembrane domain acts as an inhibitory domain by interacting 
with and inhibiting the kinase domain when ligand is not present (42, 45). The C-terminal tail 
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of PDGFR also functions as an allosteric inhibitor of the kinase domain (46). Despite these 
processes, overactivation occurs through PDGFR translocations in myeloid malignancies (47). 
Most of the PDGFR fusion proteins, including ETV6-PDGFRβ, involve a breakpoint 
occurring just before the transmembrane (TM) domain of PDGFRβ, although some contain a 
breakpoint in between the transmembrane and kinase domains (Table 2, Figure 15). 
Experimental deletion of the transmembrane domain in the ETV6-PDGFRβ fusion does not 
hinder dimerization or kinase domain activation, but does result in a decrease of cell 
proliferation and STAT5 and MAPK activation in Ba/F3 cells, suggesting that cell 
transformation relies not only on activation, but also proper alignment of the kinase domain 
(42). The inhibitory effects that the intracellular-juxtamembrane domain and C-terminal tail 
have on the WT receptor are lost or subdued in this fusion protein. 
Another common PDGFRα fusion protein is FIP1L1-PDGFRα discovered in 
myeloproliferative diseases associated with hypereosinophilia, sometimes referred to as 
chronic eosinophilic leukemia (CEL). This fusion protein is estimated to occur in 10-20% of 
eosinophilia cases (37). This chromosomal rearrangement is caused by an 800-kb deletion in 
chromosome 4 (del(4)(q12g12)), a segment including the cysteine-rich hydrophobic domain 2 
(CHIC2) locus (48). This fusion protein poses an exception to previously discussed RTK 
fusion proteins, as FIP1L1 is dispensable for PDGFRα dimerization, as shown by Ba/F3 cell 
transformation assays and by murine bone marrow transplantation using transduced bone 
marrow cells with various deletion constructs of FIP1L1-PDGFRα, where all or most of 
FIP1L1 was deleted (49). However, the FIP1 motif is involved in protein-protein interactions 
and is essential for homodimer formation of a fusion protein between FIP1L1 and retinoic 
acid receptor α (FIP1L1-RARA) in leukemia. The FIP1L1 domain does play a role in human 
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progenitor cell proliferation and contains two phosphotyrosine sites that may provide protein 
binding sites (50). The IL-3 independent proliferation of Ba/F3 cells and the dispensability of 
the FIP1L1 domain was also recently confirmed by CRISPR/Cas genome editing in Ba/F3 
cells to create the fusion at endogenous levels (51). 
The breakpoint of FIP1L1-PDGFRα lies within the juxtamembrane domain of 
PDGFRα and disrupts an inhibitory WW-like domain, which may be the key to constitutive 
receptor activation and transforming potential. The WW-like domain contains two conserved 
tryptophan residues in the juxtamembrane domain. When truncated by fusion protein 
formation, absence of one of the tryptophan residues results in constitutive receptor activation 
(49). The disruption of this domain has been noted in BCR-PDGFRα and STRN-PDGFRα 
(41, 49). Fusion proteins with the transmembrane and juxtamembrane domains intact most 
likely require an alternative dimerization and activation mechanism provided by the N-
terminal fusion partner. Although PDGFR translocations are relatively rare compared to other 
hematological translocations, their existence potentially provides an effective therapeutic 
target for cancer patients. 
 
4.5 SIGNALING ALTERATIONS RESULTING FROM RTK TRANSLOCATIONS 
ALK and ALK Fusions 
Aberrant expression of highly active RTK kinases in tissues will result in novel 
pathway activation, and may present novel therapeutic possibilities. For instance, WT ALK 
results in the activation of multiple pathways including PLCγ, JAK/STAT, PI3K/AKT, 
JUNB, MAPK, and MYCN. ALK activation of ERK and PI3K can lead to MYCN 
expression, and high MYCN levels have been linked to neuroblastoma oncogenesis (52, 53). 
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The NPM-ALK fusion protein specifically activates JUNB, Y-box transcription factor 
(YBX1), BCL2A1, matrix metalloproteinase 9 (MMP9), CDKN2A and hypoxia-inducible 
factor 1α (HIF1A) as shown in various studies using either Ba/F3 cells or ALK-positive 
ALCL human cell lines (4). 
NPM-ALK downregulates STAT1 in ALCL cells. STAT1 is known to function as a 
tumor suppressor in some cancer cell types and phosphorylation of STAT1 at Y701 leads to 
its proteasomal degradation. Tumor suppression in ALCL cells can be restored by increasing 
STAT1 by transfection with a constitutively activated STAT1 expression plasmid (54). A 
correlation is seen between invasive cell ability and the PI3K/AKT pathway activation, 
implicated in cell migration. For the fusion proteins NPM-ALK, TPM3-ALK, TFG-ALK, 
CLTC-ALK and ATIC-ALK, their ability to stimulate PI3K and AKT phosphorylation as 
shown by immunoblotting correlates with their transendothelial migration ability (55). Among 
these fusion proteins, ATIC-ALK displays the highest phosphorylation of STAT3 in mouse 
NIH3T3 cells (55).  
NPM-ALK, TPM3-ALK, TFG-ALK, CLTC-ALK and ATIC-ALK fusion proteins 
result in cell transformation, proliferation, invasion, transendothelial cell migration and tumor 
development in nude mice (55, 56). In general, the oncogenic effects of these proteins 
increase as expression levels increase; an exception is provided by the TPM3-ALK fusion 
protein, for which increased expression results in lower proliferation rates in NIH3T3 cells 
but increased invasiveness (55). Confocal microscopy and fractionation of NIH3T3 cells 
showed TPM3-ALK fusion proteins localized to the cytoskeletal fraction; thus, this effect 
may be due to the role of TPM3 as an actin filament stabilizer, potentially altering cell shape 
and movement (56). Of note, TPM3-ALK, TFG-ALK, CLTC-ALK and ATIC-ALK all 
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display cytoplasmic localization, while NPM-ALK displays both nuclear and cytoplasmic 
localization (55, 56) (Figure 16). 
 
FGFR and FGFR Fusions 
WT FGFRs result in the activation of multiple signaling pathways including PLCγ, 
PI3K/AKT, MAPK and STAT, and are important in cell proliferation and differentiation as 
demonstrated in mouse models (57). However, the signaling differences between WT FGFRs 
and FGFR fusion proteins are not completely understood. Both the ZNF198-FGFR1 and 
BCR-FGFR1 fusion proteins induce aberrant signaling through the dimerization of the kinase 
domain of FGFR1. Activation of FGFR1 through the ZNF198-FGFR1 fusion leads to 
phosphorylation or activation of FGFR1 targets such as STATs, PI3K, PLC-γ, AKT and 
MAPK as shown by expression in Ba/F3 cells. In addition, ZNF198-FGFR1 is able to activate 
a pathway involving plasminogen activator inhibitor 2 gene (PAI-2/SERPINB2), which is not 
observed in native FGFR1 signaling. The PAI-2 gene induces resistance to TNFα, which 
could suggest an alternative pathway contributing to the oncogenic potential of the ZNF198-
FGFR1 fusion, as shown by assays in HEK293 and Ba/F3 cells (58). The BCR-FGFR1 fusion 
is dependent on adaptor protein Grb2. This translocation binds Grb2 through BCR Y177, and 
was shown to induce CML-like leukemia in mice. However, BCR-FGFR1 with a mutated 
Y177 lacks Grb2 binding and causes an EMS like disease (34). 
 
PDGFR and PDGFR Fusions 
Upon activation by ligand binding, PDGFRs bind various signal transduction 
molecules via phosphotyrosine interaction motifs such as SH2 or PTB, resulting in activation 
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of downstream signaling. Some key interacting proteins include PI3K, PLCγ, Src family 
tyrosine kinases, SHP2 tyrosine phosphatase and STAT proteins (47). 
Although few PDGFR fusion proteins have been analyzed for biological function, a 
study analyzing ETV6-PDGFRβ and FIP1L1-PDGFRα found that NFκB activation was 
required for human CD34(+) cell proliferation and differentiation with a bias towards 
eosinophil lineage  (59). These fusions play a large role in human hypereosinophilia 
development in the absence of growth factors IL-3 and IL-5, whose expression usually 
supports hematopoietic stem cell differentiation to form eosinophils. IL-5 expression is 
increased in cells expressing these PDGFR fusions and, in patients, an IL-5 gene 
polymorphism was linked to a more severe disease development as shown by eosinophil 
counts and increased tissue infiltration (59).  
Multiple tyrosine phosphorylation sites (Y579/581) in PDGFRβ of ETV6-PDGFRβ 
are responsible for myeloproliferative neoplasm (MPN) development in mice. Mutation to 
phenylalanine in Y579F/Y581F mutants results in development of T-cell lymphoma, but not 
MPN (60). For FIP1L1-PDGFRα, it was identified that tyrosine 720 of PDGFRα is critical for 
SHP2 recruitment, which results in MAPK activation and Ba/F3 hematopoietic cell 
transformation. Interestingly, SHP2 recruitment represents an altered mechanism compared to 
WT PDGFR, as cell proliferation and MAPK activation occurs regardless of SHP2 interaction 
with WT receptor, as shown by expression of the human FIP1L1-PDGFRα fusion protein in 
murine Ba/F3 cells (61). Indeed, SHP2 is involved in JAK/STAT, PI3K, MAPK and other 
signaling pathway regulation, and has been implicated in leukemogenesis caused by 
mutations in KIT and FLT3 receptors (61). 
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Both ETV6-PDGFRβ and FIP1L1-PDGFRα display cytosolic expression and result in 
the activation of STAT1, STAT3 and STAT5 (Figure 16, Figure 17). STAT5 plays an 
important role in myeloproliferation by PDGFR fusion proteins as shown in both human and 
murine cell lines (59, 61, 62). STAT5 activation was also demonstrated by KANK1-PDGFRβ 
fusion protein, despite an inactivity of JAK2 and inability of JAK inhibitor to affect cell 
growth. This fusion protein is found in MPN and arises because of a t(5;9) translocation that 
results in KN Motif and Ankyrin Repeat Domains (KANK1) fused to PDGFRB. KANK1 
contributes three coiled-coil domains and an oligomerization domain, both of which are 
required for cell proliferation and upregulation of signaling (63). Interestingly, this fusion 
protein was shown to exist as a homotrimer, of which either the coiled-coil or the 
oligomerization domain may be present to allow for this motif formation (63). KANK1-
PDGFRβ also activates PLCγ and MAPK pathways, and displays cytosolic expression as 
shown in human and murine cell lines (63) (Figure 16, Figure 17). 
STAT5 activation was also shown to be essential for Ba/F3 cell transformation by the 
fusion protein Huntingtin Interacting Protein (HIP1)-PDGFRβ (64). This fusion protein also 
co-localizes with Src Homology 2-containing Inositol 5-Phosphatase (SHIP1) and displays 
cytosolic localization as shown in human HEK293T cells (64) (Figure 16). As SHIP1 is only 
expressed in hematopoietic tissues and developing spermatogonia, SHIP1 could serve as a 
potential therapeutic target (65). 
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Figure 17. Major signaling pathways activated by common RTK fusion proteins. Activation 
of STAT signaling is a commonly seen occurrence. The arrows indicate activated pathways; 
the activation of these pathways lead to cell survival and proliferation. A star indicates an 
alternate breakpoint; a triangle indicates kinase insert domain; TM is transmembrane domain; 
WW is WW-like domain; P is phosphorylation site. 
 
4.6 THERAPEUTICS FOR HEMATOPOIETIC CANCERS WITH RTK 
TRANSLOCATIONS 
There are a number of drugs that have been characterized for their potential to inhibit 
the fusion proteins discussed in this review in Table 3. These function to inhibit or reduce the 
kinase activity of the RTK fusion partner leading to reduced proliferation, increased apoptosis 
and altered downstream signaling. 
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ALK Fusions 
Crizotinib, the first ALK inhibitor to be clinically tested, is a potent, ATP-competitive, 
small molecule inhibitor initially designed against the hepatocyte growth factor receptor (c-
Met) to inhibit phosphorylation. It inhibits ALK phosphorylation and signal transduction 
leading to apoptosis in lymphoma cell lines that express the NPM-ALK fusion protein  (4, 
66). This ALK inhibitor also shows an antitumor activity in ALCL Karpas299 mouse 
xenograft models expressing the NPM-ALK fusion by inhibiting c-Met and ALK downstream 
signaling, resulting in reduction of tumor growth (66). Crizotinib has been extensively used to 
treat solid tumors containing EML4-ALK and STRN-ALK fusions in thyroid cancer and 
EML4-ALK rearrangements in non-small cell lung cancer (NSCLC) (67-69). Crizotinib is 
currently in multiple clinical trials for treating patients with ALCL (Table 3). 
Unfortunately, resistance and relapse can occur with crizotinib treatment leading to 
secondary mutations in ALK, rendering the drug ineffective (70). For instance, after treating 
human cell lines expressing the NPM-ALK fusion with high doses of crizotinib, the mutations 
L1196Q and I1171N were identified in the ALK kinase domain and shown to confer 
resistance to crizotinib in NPM-ALK expressing Ba/F3 cells (71). The L1196Q is a 
gatekeeper mutation within the ATP binding pocket, in the hinge region between the N and 
C lobes. Point mutation of this region prevents or reduces the binding of the inhibitory 
molecules and is a common occurrence in inhibitor-resistant cancers (71). The I1171N 
mutation is part of the hydrophobic spine of the kinase domain critical for tyrosine kinase 
activity (71). In RANBP2-ALK the kinase domain mutation G1269A was found in patients 
with AML and NSCLS after crizotinib treatment (70), and again this occurs in the ATP 
binding pocket and acts by decreasing TKI affinity (70). 
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An alternative selective ALK inhibitor, ceritinib, has been approved for treatment of 
NSCLC with the NPM-ALK fusion and is in a phase II trial for relapsed/refractory ALK+ 
hematologic malignancies (Table 3) (72). Another alternative, brigatinib, also leads to 
resistance through point mutations in the ALK kinase domain in NPM-ALK-amplified ALCL 
cells (73). One study finds that removal of the kinase inhibitor actually leads to apoptosis of 
the brigatinib-resistant ALCL cells by hyperactivation of the MAPK pathway (10). This 
suggests that a periodic suspension of drug treatment might potentially be beneficial for 
cancer patients with ALK translocations/amplifications. Additionally, since NPM-ALK fusion 
proteins are only active in the cytoplasm, blocking nuclear export of the fusion with selective 
inhibitors of nuclear export (SINE), such as selinexor, are currently under investigation in 
clinical trials for hematological cancers (Table 3) (10). Interestingly, a non-toxic naturally-
occurring compound found in extracts from the plant silybum marianum (milk thistle) seeds, 
silibinin, which has known anti-tumor effects, is able to inhibit NPM-ALK activation leading 
to reduced proliferation and increased apoptosis in Karpas299 and SupM2 cell lines (74). 
 
FGFR Fusions 
The importance of inhibiting aberrant FGFR signaling in FGFR-dependent 
malignancies is a well-established therapeutic target; however, specific FGFR inhibitors have 
been elusive (75). The classic FGFR inhibitor, dovitinib is a multi-targeted RTK inhibitor 
which targets FGFR, PDGFR, VEGFR, FLT3 and c-KIT. When the fusion proteins ZNF198-
FGFR1 and BCR-FGFR1 are expressed in Ba/F3 cells, treatment with dovitinib results in the 
inhibition of STAT5, MAPK, IL-3 independence and phosphorylation of the fusion proteins 
(20). Proliferation of FGFR1OP2-FGFR1 cell lines is also inhibited by dovitinib (20). A 
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phase II trial for dovitinib was recently completed in 2015 for patients with solid or 
hematologic malignancies with mutations or translocations of FGFR and other RTKs (Table 
3). The FDA-approved FGFR inhibitor, ponatinib, is also a multi-RTK inhibitor that is 
currently in multiple trials for AML and CML (75). Ponatinib shows potential for EMS 
treatment in the murine Baf3 cell lines expressing the ZNF198-FGFR1 and BCR-FGFR1 
fusions, and in the human KG1A cell line expressing the FGFR1OP2-FGFR1 fusion, leading 
to reduced proliferation, survival and phosphorylation of the FGFR1 fusion proteins and 
downstream substrates and induction of apoptosis (76). In addition, cells from EMS patients 
show reduced colony growth when treated with ponatinib (21). The specific pan-FGFR 
inhibitor, infigratinib, shows potential for EMS treatment as it is able to reduce survival and 
proliferation of TPR-FGFR1 expressing murine 32Dcl3 cells (77). It is currently in clinical 
trials for patients with FGFR genetic alterations (Table 3). 
In order to overcome the resistance that can occur with kinase inhibitors, FGFR 
irreversible inhibitors 2 (FIIN-2) and 3 (FIIN-3), have recently been developed which target 
cysteines in the ATP binding pocket. They inhibit the proliferation of transformed Ba/F3 cells 
dependent upon the gatekeeper mutants of FGFR1 or FGFR2 which often lead to drug 
resistance (78). 
 
PDGFR Fusions 
Imatinib is a multikinase inhibitor selective for ABL, PDGFR and c-Kit and is the 
most common treatment for malignancies associated with activated PDGFR. 
Hematolymphiod neoplasms associated with PDGFRα and PDGFRβ fusions such as FIP1L1-
PDGFRα and ETV6-PDGFRβ respond well to treatment with imatinib, with secondary 
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resistance being uncommon. In contrast, patients with rare and aggressive neoplasms 
containing FGFR1 fusions tend not be responsive to imatinib treatment (37). BCR-PDGFRα 
fusions found in aCML become undetectable when treated with imatinib. Diagnosing the 
difference between CML and aCML, both of which display highly similar phenotypes, is 
important to prevent treatment with an inadequate TKI (39). 
When resistance does occur, mutations have been found in the ATP binding site 
gatekeeper residue, T674I, of FIP1L1-PDGFRα. A novel TKI, S116836, has recently been 
found to be effective in inhibiting both FIP1L1-PDGFRα and FIP1L1-PDGFRα T674I 
downstream signaling, and reducing xenograft tumors in nude mice formed in response to 
BaF3 cells expressing FIP1L1-PDGFRα T674I (79). The fusion proteins driving 
hematopoietic cancers often becoming resistant, leading to additional mutations, thus 
highlighting the putative need for multiple types of drugs at various times during treatment. 
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Table 3. TKIs: Therapeutics for Hematopoietic Disorders 
RTK Drug Mechanism www.ClinicalTrials.gov  
ALK Crizotinib 
(PF02341066) 
Multi-target TKI against ALK, 
MET, ROS-1; ATP binding 
pocket 
NCT02487316; NCT01979536; 
NCT01606878; NCT02419287; 
NCT00939770; NCT00585195; 
NCT01524926 
ALK Ceritinib 
(LDK378) 
TKI against ALK; ATP 
binding pocket 
NCT01742286; NCT0729961; 
NCT02465528; NCT02186821; 
NCT02343679 
ALK Brigatinib 
(AP26113) 
TKI against ALK and EGFR; 
ATP binding pocket 
NCT01449461  
ALK Selinexor 
(KPT330) 
Selective inhibitor of nuclear 
export; modifies CRM1-cargo 
binding  
cysteine residue 
NCT02530476; NCT02573363; 
NCT02093403; NCT02416908; 
NCT02088541; NCT02299518; 
NCT02403310; NCT02249091; 
NCT02485535; NCT02212561; 
NCT02091245 
ALK Silibinin Antioxidant; biochemical 
activity under investigation 
No trials with Lymphomas 
 
FGFR Dovitinib 
(TKI258) 
Multi-target TKI against 
FGFR, PDGFR, VEGFR, 
FLT3, c-KIT; ATP binding 
pocket 
NCT01831726  
 
FGFR Ponatinib 
(AP24534) 
Multi-target TKI against 
FGFR, PDGFR, VEGFR; ATP 
binding pocket 
NCT02627677; NCT02467270; 
NCT00660920; NCT01667133; 
NCT01746836; NCT02398825; 
NCT01207440; NCT01620216 
FGFR Infigratinib 
(BGJ398) 
pan FGFR inhibitor; ATP 
binding pocket 
NCT02160041 
 
FGFR FIIN2 and 
FIIN3 
TKI against FGFR and EGFR; 
targets Cys residue(s) in ATP 
binding pocket 
No trials  
 
PDGFR Imatinib 
(STI571) 
Multi-target TKI against 
PDGFR, ABL, c-KIT; ATP 
binding pocket 
NCT00044304; NCT00038675  
PDGFR S116836 Multi-target TKI against 
gatekeeper residue of PDGFR, 
FLT, TIE2, KIT, SRC family 
kinases; ATP binding site 
No trials 
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4.7 CONCLUDING REMARKS 
Factors that influence translocations include chromosome position, DNA damage 
response pathways, transcription frequency and epigenetic factors. Transcription can be a 
driver of translocations, possibly due to DNA supercoiling and torsional stress leading to 
topoisomerase-induced breaks (6). In this review, we discussed translocations involving 
RTKs in hematopoietic disorders including ALK, FGFR, PDGFR, RET, CSF1R and NTRK3. 
Although many translocations have been identified, activation pathways and mechanistic 
insight for many of these RTK fusions in cancer pathogenesis have yet to be elucidated.  
The discovery of these translocations has already facilitated the use of novel RTK 
inhibitor therapies to treat patients who are positive for translocation-induced cancers. While 
some RTK-targeted therapies have proven to be beneficial in various malignancies, 
challenges remain as many cases result in drug resistance or relapse. Therefore, there is an 
urgent need for additional approaches to the characterization and treatment of RTK-
translocation induced cancers. The identification of chromosomal translocations occurring in 
different cancers will be essential, and the utilization of multiple drug types during different 
treatment stages may prove to be efficacious. It is crucial that the robust discovery and 
characterization of these RTK fusions continue to allow the development of finely tuned 
therapies for hematopoietic disorders. 
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